

CHAPTER II

NICOTINE: PHARMACOKINETICS, METABOLISM, AND PHARMACODYNAMICS

CONTENTS

Introduction	25
<hr/>	
Nicotine and Other Alkaloids in Various Tobacco Products	26
<hr/>	
Pharmacokinetics and Metabolism of Nicotine	29
Absorption of Nicotine	29
Distribution of Nicotine in Body Tissues	31
Elimination of Nicotine	33
Pathways of Nicotine Metabolism.....	34
Rate of Nicotine Metabolism	37
Renal Excretion.....	37
Nicotine and Cotinine Blood Levels During Tobacco Use	37
Nicotine Levels.....	37
Cotinine Levels.....	38
Intake of Nicotine	40
Cigarette Smoking.....	40
Elimination Rate as a Determinant of Nicotine Intake by Cigarette Smoking	40
Biochemical Markers of Nicotine Intake	41
Analytical Methods for Measuring Nicotine and Cotinine in Biological Fluids	42
<hr/>	
Pharmacodynamics of Nicotine	43
General Considerations	43
Dose-Response	44
Tolerance	44
Acute Sensitivity	46
Human Studies.....	46
Animal Studies	46
Mechanisms of Differences in Acute Sensitivity	47
Tachyphylaxis (Acute Tolerance)	47
Human Studies.....	47
Animal Studies.....	49
Mechanisms of Tachyphylaxis	49
Chronic Tolerance.....	50
Human Studies.....	50

Animal Studies	51
Mechanisms of Chronic Tolerance	53
Pharmacodynamics of Nicotine and Cigarette Smoking.....	55
<hr/>	
Constituents of Tobacco Smoke Other Than Nicotine	
With Potential Behavioral Effects	56
Minor Tobacco Alkaloids	56
“Tar” and Selected Constituents of Tobacco Smoke	
Which Contribute to Taste and Aroma.....	58
Carbon Monoxide.....	59
Acetaldehyde and Other Smoke Constituents.....	60
<hr/>	
Summary and Conclusions	60
<hr/>	
References.....	62

Introduction

Chemicals with behavioral and physiological activity are delivered to tobacco users when they smoke a cigarette or use other tobacco products. Whether these chemicals are absorbed in quantities that are of biological significance and whether such absorption is related to the behavior of the tobacco user are critical issues in understanding their role in addictive tobacco use. The scientific study of the absorption processes, distribution within the body, and elimination from the body of drugs and chemicals is called pharmacokinetics. The study of drug and other chemical actions on the body, over time, is called pharmacodynamics.

Pharmacokinetic and pharmacodynamic studies can be done separately or together. An example of the latter is when a drug is administered and its concentrations in the blood and its behavioral and physiological actions are measured over time. Such studies can reveal relationships among the dose of a drug, levels in the blood, and effects on body functions.

The pharmacokinetics and pharmacodynamics of some tobacco smoke constituents, particularly nicotine and carbon monoxide, have been extensively studied. These studies show an orderly relationship between the use of tobacco and the absorption of nicotine. Similarly, the effects on behavioral and physiological functions, although complex, are orderly and related to the pharmacokinetics of nicotine. These data will be reviewed in this Section. Research shows that nicotine is well absorbed from tobacco; that it is distributed rapidly and in biologically active concentrations to body organs, including the brain; and that nicotine is the major cause of the predominant behavioral effects of tobacco and some of its physiologic consequences.

One effect of nicotine, development of tolerance to its own actions, is similar to that produced by other addicting drugs. Tolerance refers to decreasing responsiveness to a drug or chemical such that larger doses are required to produce the same magnitude of effect. Tolerance to many actions of nicotine occurs in animals and humans. Evidence for tolerance to nicotine and mechanisms of tolerance development will be reviewed in this Chapter (see also Chapter VI).

Although nicotine has long been considered as the primary pharmacologic reason for tobacco use, and the source of a number of the physiological effects of tobacco, thousands of other chemicals are present in tobacco. Most of these are delivered in such small quantities that they appear to have little or no behavioral consequence. However, a few chemicals do appear to have behavioral effects and there is a potential for numerous chemical interactions that conceivably could have behavioral consequences. This Chapter will conclude with an examination of tobacco smoke constituents

other than nicotine that may contribute to behavioral effects of cigarette smoking.


The toxicity of nicotine is discussed in detail in Appendix B.

Nicotine and Other Alkaloids in Various Tobacco Products


Nicotine is a tertiary amine composed of a pyridine and a pyrrolidine ring (Figure 1). Nicotine may exist in two different three-dimensionally structured shapes, called stereoisomers. Tobacco contains only (S)-nicotine (also called l-nicotine), which is the most pharmacologically active form. Tobacco smoke also contains the less potent (R)-nicotine (also called d-nicotine) in quantities up to 10 percent of the total nicotine present (Pool, Godin, Crooks 1985). Presumably some racemization occurs during the combustion process.

The nicotine yield of cigarettes, as determined by standardized smoking machine tests, is available for most brands. However, the amount of nicotine in cigarettes or other tobacco products is not specified by manufacturers. Because tobacco is a plant product, there are differences in the amount of nicotine among and within different types and strains of tobacco, including variations in different parts of the plant, as well as differences related to growing conditions. Table 1 shows concentrations of nicotine and other alkaloids in several different tobacco leaves used in making commercial tobacco products. Within a tobacco plant, leaves harvested from higher stalk positions have higher concentrations of nicotine than from lower stalk positions; ribs and stems of the leaves have the least (Rathkamp, Tso, Hoffmann 1973). Combining different varieties of tobacco and different parts of the plant is a way to change the nicotine concentration of commercial tobacco.


In a study of amounts of nicotine in the tobacco of 15 American cigarette brands of differing machine-determined yields (Benowitz, Hall et al. 1983), tobacco contained on average 1.5 percent nicotine by weight. Nicotine yield of the cigarettes, as defined by Federal Trade Commission smoking machine tests, was correlated inversely with nicotine concentrations in the tobacco. Thus, tobacco of lower-yield cigarettes tended to have higher concentrations of nicotine than did tobacco of higher-yield cigarettes. However, lower-yield cigarettes also contained less tobacco per cigarette, so the total amount of nicotine contained per cigarette, averaging 8.4 mg, was similar in different brands. Thus, low-yield cigarettes are low yield not because of lower concentrations of nicotine in the tobacco, but because they contain less tobacco and have characteristics which remove tar and nicotine by filtration or dilution of smoke with air. Concentrations of nicotine in commercial tobacco products are summarized in Table 2.




NICOTINE




ANATABINE




ANABASINE




ANABASEINE




NORNICOTINE




N'-METHYLANATABINE




N'-METHYLANABASINE




2,3-DIPYRIDYL




N'-NITROSONORNICOTINE




NICOTYRINE




NORNICOTYRINE




METANICOTINE




NICOTINE N-OXIDE
(OXYNICOTINE)



COTININE



6'-OXOANABASINE



PSEUDOXYNICOTINE

Although the major alkaloid in tobacco is nicotine, there are other alkaloids in tobacco which may be of pharmacologic importance. These include nornicotine, anabasine, myosmine, nicotyrine, and anatabine (Figure 1). These substances make up 8 to 12 percent of the total alkaloid content of tobacco products (Table 1) (Piade and Hoffmann 1980). In some varieties of tobacco, nornicotine concentrations exceed those of nicotine (Schmeltz and Hoffmann 1977).

Typical quantities of the minor alkaloids in the smoke of one cigarette are: nornicotine (27 to 88 μg), cotinine (9 to 50 μg), anabasine (3 to 12 μg), anatabine (4 to 14 μg), myosmine (9 μg), and 2,3' dipyridyl (7 to 27 μg). N'-methylanabasine, nicotyrine, nornicotyrine, and nicotine-N'-oxide have also been identified in cigarette smoke (Schmeltz and Hoffmann 1977). Puffing characteristics, especially puff frequency, influence the delivery of the component alkaloids (Bush, Grünwald, Davis 1972).

TABLE 1.-Alkaloid content of various tobaccos (mg/kg, dry basis)

Alkaloid	Dark commercial tobacco			
	A	B	Burley	Bright
Nicotine	11,500	10,000	15,400	12,900
Nornicotine	550	200	630	210
Anatabine	360	380	570	600
Anabasine	140	150	90	150
Cotinine	195	140	90	40
Myosmine	45	50	60	30
2,3'-Dipyridyl	100	110	30	10
N'-Formyl-nornicotine	175	210	140	40

SOURCE Piade and Hoffmann (1980).

TABLE 2.--Nicotine content of various tobacco products

Product	Number of brands tested	Concentration of nicotine (mg/g tobacco)	Typical single dose ^a (g tobacco)	Nicotine in single dose ^a (mg)	Nicotine in dose typically consumed in a day
Cigarettes ¹	15	15.7 (13.3-26.9) ^b	0.54	8.4	168 mg/20 cigs
Moist snuff ^{2,3}	8	10.5 (6.1-16.6)	1.4	14.5	157 mg/15 g
Chewing tobacco ^{3,4}	2	16.8 (9.1-24.5)	7.9	133	1,176 mg/70 g

Single dose refers to a cigarette or an amount of smokeless tobacco placed in the mouth.

Range.

SOURCE: ¹Benowitz, Hall et al. (1983); ²Kozlowski et al. (1981); ³Gritz et al. (1981); ⁴Benowitz, Porchet et al. (in press).

Nornicotine and anabasine have pharmacologic activity qualitatively similar to that of nicotine, with potencies of 20 to 75 percent compared with that of nicotine, depending on the test system and the animal (Clark, Rand, Vanov 1965). In addition to direct activity, some of the minor alkaloids may influence the effects of nicotine. For example, nicotyrine inhibits the metabolism of nicotine in animals (Stalhandske and Slanina 1982).

The pharmacology of the minor tobacco alkaloids is discussed in more detail in the last section of this Chapter.

Pharmacokinetics and Metabolism of Nicotine

Absorption of Nicotine

Nicotine is distilled from burning tobacco and is carried proximally on tar droplets (mass median diameter 0.3 to 0.5 μm) and probably also in the vapor phase (Eudy et al. 1985), which are inhaled. Absorption of nicotine across biological membranes depends on pH (Armitage and Turner 1970; Schievelbein et al. 1973). Nicotine is a weak base with a pKa (index of ionic dissociation) of 8.0 (aqueous solution, 25°C). This means that at pH 8.0, 50 percent of nicotine is ionized and 50 percent is nonionized. In its ionized state, such as in acidic environments, nicotine does not rapidly cross membranes.

The pH of tobacco smoke is important in determining absorption of nicotine from different sites within the body. The pH of individual puffs of cigarettes made of flue-cured tobacco, the predominant tobacco in most American cigarettes, is acidic and decreases progressively with sequential puffs from pH 6.0 to 5.5 (Brunnemann and Hoffmann 1974). At these pHs, the nicotine is almost completely ionized. As a consequence, there is little buccal absorption of nicotine from cigarette smoke, even when it is held in the mouth (Gori, Benowitz, Lynch 1986). The smoke from air-cured tobaccos, the predominant tobacco in pipes, cigars, and in a few European cigarettes, is alkaline with progressive puffs increasing its pH from 6.5 to 7.5 or higher (Brunneman and Hoffmann 1974). At alkaline pH, nicotine is largely nonionized and readily crosses membranes. Nicotine from products delivering smoke of alkaline pH is well absorbed through the mouth (Armitage et al. 1978; Russell, Raw, Jarvis 1980).

When tobacco smoke reaches the small airways and alveoli of the lung, the nicotine is rapidly absorbed. The rapid absorption of nicotine from cigarette smoke through the lung occurs because of the huge surface area of the alveoli and small airways and because of dissolution of nicotine at physiological pH (approximately 7.4), which facilitates transfer across cell membranes. Concentrations of nicotine in blood rise quickly during cigarette smoking and peak at its completion (Figure 2). Armitage and coworkers (1975), measuring exhalation of radiolabeled nicotine, found that four cigarette smokers absorbed 82 to 92 percent of the nicotine in mainstream smoke, another smoker presumed to be a noninhaler absorbed 29 percent, and three nonsmokers (who were instructed to smoke as deeply as possible) absorbed 30 to 66 percent.

Chewing tobacco, snuff, and nicotine polacrilex gum are of alkaline pH as a result of tobacco selection and/or buffering with additives by the manufacturer. The alkaline pH facilitates absorption of nicotine through mucous membranes. The rate of nicotine absorption from smokeless tobacco depends on the product and the




FIGURE 2.—Blood nicotine concentrations during and after smoking cigarettes (1 1/3 cigarettes), using oral snuff (2.5 g), using chewing tobacco (average, 7.9 g), and chewing nicotine gum (two 2-mg pieces)

SOURCE: Benowitz, Porchet et al. (1988).

route of administration. With fine-ground nasal snuff, blood levels of nicotine rise almost as fast as those observed after cigarette smoking

(Russell et al. 1981). The rate of nicotine absorption with the use of oral snuff and chewing tobacco is more gradual. Nicotine is poorly absorbed from the stomach due to the acidity of gastric fluid (Travell 1960), but is well absorbed in the small intestine (Jenner, Gorrod, Beckett 1973), which has a more alkaline pH and a large surface area. Bioavailability of nicotine from the gastrointestinal tract (that is, swallowed nicotine) is incomplete because of presystemic (first pass) metabolism, whereby, after absorption into the portal venous circulation, nicotine is metabolized by the liver before it reaches the systemic venous circulation. This is in contrast to nicotine absorbed through the lungs or oral/nasal mucosa, which reaches the systemic circulation without first passing through the liver. Nicotine base can be absorbed through the skin, and there have been cases of poisoning after skin contact with pesticides containing nicotine (Faulkner 1933; Benowitz, Lake et al. 1987; Saxena and Scheman 1985). Likewise, there is evidence of cutaneous absorption of and toxicity from nicotine in tobacco field workers (Gehlbach et al. 1975).

Because of the complexity of cigarette smoking processes and use of smokeless tobacco products, the dose of nicotine cannot be predicted from the nicotine content of the tobacco or its absorption characteristics. To determine the dose, one needs to measure blood levels and know how fast the individual eliminates nicotine. This topic, estimation of systemic doses of nicotine consumed from various tobacco products, will be considered in a later section after discussion of relevant pharmacokinetic issues.

Distribution of Nicotine in Body Tissues

After absorption into the blood, which is at pH 7.4, about 69 percent of the nicotine is ionized and 31 percent nonionized. Binding to plasma proteins is less than 5 percent (Benowitz, Jacob et al. 1982). The drug is distributed extensively to body tissues with a steady state volume of distribution averaging 180 liters (2.6 times body weight (in kilograms)) (Table 3). This means that when nicotine concentrations have fully equilibrated, the amount of nicotine in the body tissues is 2.6 times the amount predicted by the product of blood concentration and body weight. The pattern of tissue uptake cannot be studied in humans, but it has been examined in tissues of rabbits by measuring concentrations of nicotine in various tissues after infusion of nicotine to steady state (Table 4). Spleen, liver, lungs, and brain have high affinity for nicotine, whereas the affinity of adipose tissue is relatively low.

After rapid intravenous (i.v.) injection, concentrations of nicotine decline rapidly because of tissue uptake of the drug. Shortly after i.v. injection, concentrations in arterial blood, lung, and brain are high, while concentrations in tissues such as muscle and adipose (major storage tissues at steady state) are low. The consequence of this

TABLE 3.--Human pharmacokinetics of nicotine and cotinine

	Nicotine	Cotinine
Half-life	120 min	18 hr
Volume of distribution	180 L	88 L
Total clearance	1,300 mL/min	72 mL/min
Renal clearance	200 mL/min (acid urine)	12 mL/min
Nonrenal clearance	1,100 mL/min	60 mL/min

SOURCE: Average values based on data from Benowitz, Jacob et al. (1982) and Benowitz, Kuyt et al. (1983).

TABLE 4.--Steady state distribution of nicotine

Tissue	Tissue to blood ratio
Blood	1.0
Brain	3.0
Heart	3.7
Muscle	2.0
Adipose	0.5
Kidney	21.6
Liver	3.7
Lung	2.0
Gastrointestinal	3.5

NOTE: Tissue to blood nicotine concentration ratios based on 24-hr constant i.v. infusion of nicotine in rabbits.
SOURCE: Benowitz (1986b).

distribution pattern is that uptake into the brain is rapid, occurring within 1 or 2 min, and blood levels fall because of peripheral tissue uptake for 20 or 30 min after administration. Thereafter, blood concentrations decline more slowly, as determined by rates of elimination and rates of distribution out of storage tissues.

Rapid nicotine uptake into the brain has been demonstrated in animal studies. Oldendorf (1974) showed a high degree of nicotine uptake from blood in the first pass through the brains of rats. Schmitterlow and colleagues (1967) showed by autoradiographic techniques that high levels of nicotine were present in the brain 5 min after i.v. injections in mice and that most nicotine had been

cleared from the brain by 30 min. Stalhandske (1970) showed that intravenously injected ^{14}C -nicotine is immediately taken up in the brains of mice, reaching a maximum concentration within 1 min after injection. Similar findings based on positron emission tomography of the brain were seen after injection of ^{11}C -nicotine in monkeys (Maziere et al. 1976).

Nicotine inhaled in tobacco smoke enters the blood almost as rapidly as after rapid i.v. injection except that the entry point into the circulation is pulmonary rather than systemic venous. Because of delivery into the lung, peak nicotine levels may be higher and lag time between smoking and entry into the brain shorter than after i.v. injection. After smoking, the action of nicotine on the brain is expected to occur quickly. Rapid onset of effects after a puff is believed to provide optimal reinforcement for the development of drug dependence. The effect of nicotine declines as it is distributed to other tissues. The distribution half-life, which describes the movement of nicotine from the blood and other rapidly perfused tissues, such as the brain, to other body tissues, is about 9 min (Feyerabend et al. 1985). Distribution kinetics, rather than elimination kinetics (half-life, about 2 hr), determine the time course of central nervous system (CNS) actions of nicotine after smoking a single cigarette.

Nicotine is secreted into saliva (Russell and Feyerabend 1978). Passage of saliva containing nicotine into the stomach, combined with the trapping of nicotine in the acidic gastric fluid and reabsorption from the small bowel, provides a potential route for enteric nicotine recirculation. This recirculation may account for some of the oscillations in the terminal decline phase of nicotine blood levels after i.v. nicotine infusion or cessation of smoking (Russell 1976).

Nicotine freely crosses the placenta and has been found in amniotic fluid and the umbilical cord blood of neonates (Hibberd, O'Connor, Gorrod 1978; Luck et al. 1982; Van Vunakis, Langone, Milunsky 1974). Nicotine is found in breast milk and the breast fluid of nonlactating women (Petrakis et al. 1978; Hill and Wynder 1979) and in cervical mucous secretions (Sasson et al. 1985). Nicotine is also found in the freshly shampooed hair of smokers and of nonsmokers environmentally exposed to tobacco smoke (Haley and Hoffmann 1985).

Elimination of Nicotine

Nicotine is extensively metabolized, primarily in the liver, but also to a small extent in the lung (Turner et al. 1975). Renal excretion of unchanged nicotine depends on urinary pH and urine flow, and may range from 2 to 35 percent, but typically accounts for 5 to 10 percent of total elimination (Benowitz, Kuyt et al. 1983; Rosenberg et al. 1980).




FIGURE 3.—Major pathways of nicotine metabolism

Pathways of Nicotine Metabolism

The primary metabolites of nicotine are cotinine and nicotine-N'-oxide (Figure 3). Cotinine is formed in the liver in a two-step process, the first of which involves oxidation of position 5 of the pyrrolidine ring in a cytochrome P-450-mediated process to nicotine-D¹⁽⁵⁾-iminium ion (Peterson, Trevor, Castagnoli 1987). In the second step the iminium ion is metabolized by a cytoplasmic aldehyde oxidase to cotinine (Hibberd and Gorrod 1983).

Cotinine itself is also extensively metabolized, with only about 17 percent excreted unchanged in the urine (Benowitz, Kuyt et al. 1983). Several metabolites of cotinine have been reported, including *trans*-3'-hydroxycotinine (McKennis, Turnbull et al. 1963), 5'-hydroxycotinine (Bowman and McKennis 1962), cotinine-N-oxide (Shulgin et al. 1987), and cotinine methonium ion (McKennis, Turnbull, Bowman 1963) (see Figure 4). Little is known about the quantitative importance of these metabolites. *Trans*-3'-hydroxycotinine appears to be a major metabolite (Jacob, Benowitz, Shulgin 1988; Neurath et al. 1987), with urinary concentrations exceeding cotinine concentrations by twofold to threefold. Cotinine N-oxide is a minor metabolite in humans, accounting for approximately 3 percent of ingested nicotine (Shulgin et al. 1987). Subsequent oxidative degradation of the pyrrolidine ring gives rise to 3-pyridylacetic acid. This compound has been identified in human urine (McKennis, Schwartz, Bowman 1964), but no quantitative data are available.




FIGURE 4.—Structures of nicotine and its major metabolites

SOURCE: P. Jacob III (with permission).

Nicotine-1'-N-oxide is quantitatively a minor metabolite of nicotine. Oxidation of the nitrogen atom of the pyrrolidine ring depends on a microsomal flavoprotein system and produces a mixture of the two diastereoisomers, 1'-(R)-2'-(S)cis- and 1'-(S)2'-(S)-trans- nicotine-1'-N'-oxide (Booth and Boyland 1970). After i.v. injection, 100 percent of nicotine-N'-oxide is excreted unchanged in the urine, indicating no further metabolism (Beckett, Gorrod, Jenner 1971a). However, after oral administration only 30 percent is recovered in the urine as nicotine-N'-oxide; the remainder is recovered as nicotine and its metabolites. To evaluate the possibility of reduction of nicotine-N'-oxide in the gastrointestinal tract, rectal administration of nicotine-N'-oxide was performed for experimental purposes. Less than 10 percent was recovered in the urine as nicotine-N'-oxide (Beckett, Gorrod, Jenner 1970). These findings indicate reduction of nicotine-N'-oxide back to nicotine within the human gastrointestinal tract, believed to be a consequence of bacterial action.

Experiments in rats indicate that significant amounts of nicotine-N'-oxide are converted to nicotine both in vitro and in vivo (Dajani, Gorrod, Beckett 1975a,b). Nicotine and cotinine have been measured in the blood of rats administered nicotine-N,N'-dioxide and nicotine-N'-oxide in drinking water (Sepkovic et al. 1984, 1986). Thus, while reduction of nicotine-N'-oxide to nicotine appears to be bacterial in humans, it may be mediated by endogenous enzymes in other species.

Quantitative aspects of the conversion of nicotine to its metabolites have not been well defined. Studies of cotinine excretion in urine collected for 24 hr after i.v. nicotine injection indicate less than 10 percent of nicotine is excreted as cotinine in nonsmokers compared with an average of 25 percent in smokers (Beckett, Gorrod, Jenner 1971b). Another study, comparing 24-hr urinary excretion of cotinine with nicotine content of cigarette butts after smoking, indicated 46 percent recovery as cotinine (Schievelbein 1982). However, both of these studies underestimate the conversion of nicotine to cotinine because the urine collection period was too short. In cigarette smokers, cotinine has a half-life averaging 18 to 20 hr (Benowitz, Kuyt et al. 1983), so that in 24 hr only a little more than half of cotinine is recovered. Urine collection for at least 72 hr is necessary to recover more than 90 percent of cotinine in most subjects. In addition, since only 17 percent of cotinine is excreted unchanged (Benowitz, Kuyt et al. 1983), urinary recovery analysis underestimates the cotinine generation rate.

At steady state, the rate of metabolite excretion reflects the rate at which the metabolites are generated. After i.v. dosing, 100 percent of nicotine-N'-oxide but only 17 percent of cotinine are excreted unchanged in the urine. Based on a ratio of urinary cotinine to nicotine-N'-oxide of 2.9 and based on excretion of that 17 percent of

cotinine and 100 percent of nicotine-N'-oxide unchanged in the urine, the relative generation rate of cotinine compared with that of nicotine-N'-oxide is calculated to be 17 to 1 (Benowitz 1986b). Because 4 percent of nicotine is excreted as nicotine-N'-oxide (Jacob et al. 1986; Beckett, Gorrod, Jenner 1971a), about 70 percent of nicotine appears to be converted to cotinine. Quantitative data on other metabolites that may have pharmacologic activity, such as nicotine isomethonium ion and nornicotine, are not available.

Rate of Nicotine Metabolism

The rate of nicotine metabolism can be determined by measuring blood levels after administration of a known nicotine dose. In one study, cigarette smokers were given i.v. infusions of nicotine for 30 to 60 min, and total and renal clearances were computed (Benowitz, Jacob et al. 1982). Total clearance (a term which describes the capacity to eliminate a drug) averaged 1,300 mL/min. Nonrenal clearance averaged 1,100 mL/min (Table 3), which represents about 70 percent of liver blood flow. Because nicotine is metabolized mainly by the liver (data in animals indicate only a small degree of metabolism by the lung) (Turner, Sillett, McNicol 1977), this means that about 70 percent of the drug is extracted from the blood in each pass through the liver. On the average, 85 or 90 percent of nicotine is metabolized by the liver.

Renal Excretion

Nicotine is excreted by glomerular filtration and tubular secretion within the kidney. Depending on urinary pH and urine flow rate, variable amounts of nicotine are reabsorbed by the kidney tubules. In acidic urine, where nicotine is mostly ionized and tubular reabsorption is minimized, renal clearance of nicotine may be as high as 600 mL/min (urinary pH 4.4) (Benowitz, Kuyt et al. 1983; Rosenberg et al. 1980). In alkaline urine, a larger fraction of nicotine is not ionized. Tubular reabsorption of nonionized nicotine results in lower rate of excretion and reduced renal clearances as low as 17 mL/min (urine pH 7.0). When urine pH is uncontrolled, averaging 5.8, renal clearance averages about 100 mL/min, accounting for the elimination of 10 to 15 percent of the daily nicotine intake.

Nicotine and Cotinine Blood Levels During Tobacco Use

Nicotine Levels

Plasma nicotine concentrations (or concentrations in blood, which are similar) sampled in the afternoon in smokers generally range from 10 to 50 ng/mL. The increment in blood nicotine concentration after smoking a single cigarette ranges from 5 to 30 ng/mL, depending on how the cigarette is smoked (Armitage et al. 1975;

Herning et al. 1983; Isaac and Rand 1972). Peak blood levels of nicotine are similar, although the rate of nicotine increase is slower for cigar smokers and snuff and chewing tobacco users compared with that for cigarette smokers (Armitage et al. 1978; Turner, Sillett, McNicol 1977; Gritz et al. 1981; Russell, Raw, Jarvis 1980; Russell et al. 1981) (Figure 2). Pipe smokers, particularly those who have previously smoked cigarettes and who inhale, may have blood and urine levels of nicotine as high as those of cigarette smokers (McCusker, McNabb, Bone 1982; Turner, Sillett, McNicol 1977; Wald et al. 1984).

The earliest published studies of nicotine elimination kinetics reported half-lives of 20 to 40 min (Armitage et al. 1975; Isaac and Rand 1972). In those studies, drug blood levels were followed only for 30 to 60 min, which is not long enough to determine the elimination half-life. Thus, half-lives were based on blood levels which included the distribution phase. When blood levels are followed for several hours after the end of nicotine infusion, a log-linear decline of blood levels with a half-life of about 2 hr is observed (Benowitz, Jacob et al. 1982; Feyerabend, Ings, Russell 1985).

The half-life of a drug is useful in predicting its accumulation rate in the body with repetitive doses and the time course of its decline after cessation of dosing. Assuming a half-life of 2 hr, one would predict nicotine to accumulate over 6 to 8 hr (3 to 4 half-lives) of regular smoking and persist at significant nicotine levels for 6 to 8 hr after cessation of smoking. If a smoker smokes until bedtime, significant nicotine levels should persist all night. Studies of blood levels in regular cigarette smokers confirm these predictions (Figure 5) (Russell and Feyerabend 1978; Benowitz, Kuyt, Jacob 1982). Peaks and troughs follow the use of each cigarette, but as the day progresses, trough levels rise and the influence of peak levels becomes less important. Thus, nicotine is not a drug to which people are exposed intermittently and that is eliminated rapidly from the body. To the contrary, smoking represents a multiple dosing situation with considerable accumulation during smoking and with persistent levels for 24 hr of each day.

Cotinine Levels

Cotinine levels are of particular interest as qualitative markers of tobacco use and quantitative indicators of nicotine intake. Cotinine is present in the blood of smokers in much higher concentrations than nicotine. Cotinine blood levels average about 250 to 300 ng/mL in groups of cigarette smokers (Benowitz, Hall et al. 1983; Haley, Axelrad, Tilton 1983; Langone, Van Vunakis, Hill 1975; Zeidenberg et al. 1977). After stopping smoking, levels decline with a half-life averaging 18 to 20 hr (range 11 to 37 hr). But because of the long half-life, there is much less fluctuation in cotinine concentrations





FIGURE 5.—Blood nicotine and carboxyhemoglobin concentrations in subjects smoking high nicotine (2.5 mg) and low nicotine (0.4 mg) Kentucky reference cigarettes and their usual brand (average nicotine yield, 1.2 mg) of cigarettes

NOTE: Subjects smoked on a fixed schedule of 1 cigarette every half hour from 8:30 a.m. to 11:00 p.m., for a total of 30 cigarettes/day; blood samples were collected just before the next scheduled cigarette.
 SOURCE: Benowitz, Kuyt, Jacob (1982).

throughout the day than in nicotine concentrations. As expected, there is a gradual increase in cotinine levels during the day, peaking at the end of smoking and persisting in high concentrations overnight.

Intake of Nicotine

Cigarette Smoking

Nicotine intake from single cigarettes has been measured by spiking cigarettes with ¹⁴C-labeled nicotine (Armitage et al. 1975). That study of eight subjects, each smoking a single filter-tipped cigarette, indicated an intake range of 0.36 to 2.62 mg. Intake was higher in smokers than in nonsmokers. Intake of nicotine from smoking a single cigarette or with daily cigarette smoking has been estimated by methods similar to those used in drug bioavailability studies (Benowitz and Jacob 1984; Feyerabend, Ings, Russell 1985). Metabolic clearance of nicotine was determined after i.v. injection. Metabolic clearance data were then used in conjunction with blood and urinary concentrations of nicotine measured during a period of smoking to determine the intake of nicotine. In five subjects, average intake of nicotine per cigarette was 1.06 mg (range, 0.58 to 1.49 mg) (Feyerabend, Ings, Russell 1985). In 22 cigarette smokers, 13 men and 9 women who smoked an average of 36 cigarettes/day (range 20 to 62), the average daily intake was 37.6 mg, with a range from 10.5 to 78.6 mg (Benowitz and Jacob 1984). Nicotine intake per cigarette averaged 1.0 mg (range 0.37 to 1.56 mg). Intake per cigarette did not correlate with yields obtained by smoking machine using standard Federal Trade Commission methods. This is because smoking machines smoke cigarettes in a uniform way, using a fixed puff volume (35 mL), flow rate (over 2 set), and interval (every minute). Smokers smoke cigarettes differently, changing their puffing behavior to obtain the desired amount of tobacco smoke and nicotine.

Elimination Rate as a Determinant of Nicotine Intake by Cigarette Smoking

There is considerable evidence that smokers adjust their smoking behavior to try to regulate or maintain a particular level of nicotine in the body (Gritz 1980; Russell 1976). For example, when the availability of cigarettes is restricted, habitual smokers can increase intake of nicotine per cigarette 300 percent compared with the intake of unrestricted smoking (Benowitz, Jacob, Koslowski et al. 1986).

Techniques for measuring daily intake of nicotine (Benowitz and Jacob 1984) have been applied to study the influence of elimination on nicotine intake. The rate of renal elimination of nicotine was manipulated by administration of ammonium chloride or sodium

bicarbonate to acidify or alkalinize the urine, respectively (Benowitz and Jacob 1985). Compared with daily excretion during placebo treatment (3.9 mg nicotine/day), acid loading increased (to 12 mg/day) and alkaline loading decreased (to 0.9 mg/day) daily excretion of nicotine. The total intake of nicotine averaged 38 mg/day. Average blood nicotine concentrations were similar in placebo and bicarbonate treatment conditions but were 15 percent lower during ammonium chloride treatment. Daily intake of nicotine was 18 percent higher during acid loading, indicating compensation for increased urinary loss. The compensatory increase in nicotine consumption was only partial, replacing about half of the excess urinary nicotine loss. Bicarbonate treatment had no effect on nicotine consumption, consistent with the small magnitude of effect on excretions of nicotine in comparison to total daily intake.

These results seem compatible with the suggestion of Schachter (1978) that emotional stress, which results in more acidic urine, might accelerate nicotine elimination from the body and thereby increase cigarette smoking. But caution must be exercised in applying these findings to usual smoking situations. These studies were performed under conditions of extreme urinary acidification or alkalinization, so that the changes in renal clearance would be maximized. Even with extreme differences in urinary pH, differences in overall nicotine elimination rate and smoking behavior were modest. This is because renal excretion is a minor pathway for elimination of nicotine; most is metabolized. Smaller changes in urinary pH, such as occur spontaneously throughout the day or that might be related to stressful events, would not be expected to substantially influence nicotine elimination or smoking behavior.

Biochemical Markers of Nicotine Intake

Absorption of nicotine from tobacco smoke provides a means of verification and quantitation of tobacco consumption. The general strategy is to measure concentrations of nicotine, its metabolites (such as cotinine), or other chemicals associated with tobacco smoke in biological fluids such as blood, urine, or saliva. Different measures vary in sensitivity, specificity, and difficulty of analysis. Different investigators have used blood or urinary nicotine concentrations, blood or salivary or urinary cotinine concentrations, expired carbon monoxide or carboxyhemoglobin concentrations, or plasma or salivary thiocyanate (a metabolite of hydrogen cyanide, a vapor phase constituent) concentrations as measures of tobacco smoke consumption.

Relationships among daily intake of nicotine, daily exposure to nicotine (that is, blood concentrations of nicotine integrated over 24 hr), various parameters of cigarette consumption, and different measures of nicotine intake have been examined experimentally

during ad libitum cigarette smoking on a research ward (Benowitz and Jacob 1984). The best biochemical correlate to nicotine intake and exposure in this study was a random blood nicotine concentration measured at 4 p.m. This level did not depend on when the last cigarette was smoked. This finding is consistent with the observation that nicotine levels accumulate throughout the day and plateau in the early afternoon (see Figure 5). At steady state, with regular smoking throughout the day, there should be a reasonably good correlation between nicotine concentrations and daily intake. Carboxyhemoglobin (COHb) concentrations in the afternoon were the next best markers of nicotine intake. Also, morning (8 a.m.) levels of nicotine and COHb correlated with intake, presumably reflecting persistence of nicotine and COHb in the blood from exposure on the previous day.

Although cotinine is a highly specific marker for nicotine exposure, blood levels of cotinine across subjects in this study did not correlate as closely with nicotine intake as did blood levels of nicotine or COHb (Benowitz and Jacob 1984). This is probably due to individual variability in fractional conversion of nicotine to cotinine and in the elimination rate of cotinine itself.

Because of its relatively long half-life, cotinine levels are less sensitive than nicotine levels to smoking pattern, that is, when the last cigarette was smoked. For longitudinal within-subject studies, the cotinine level would be expected to be a good marker of changes in nicotine intake. Cotinine measurements have become the most widely accepted method for assessing the intake of nicotine in long-term studies of tobacco use (see also Chapter V).

As expected by the known variation in renal clearance due to effects of urinary flow and pH, urinary concentrations of nicotine did not correlate well with nicotine intake (Benowitz and Jacob 1984). In contrast, urinary cotinine, which is less influenced by urinary flow or pH, was as good a marker as blood cotinine concentration. Salivary and urinary cotinine concentrations correlate well ($r=0.8$ to 0.9) with blood cotinine concentrations (Haley, Axelrad, Tilton 1983; Jarvis et al. 1984). Therefore, salivary or urine cotinine concentrations should be almost as useful as blood levels in indicating nicotine intake.

Analytical Methods for Measuring Nicotine and Cotinine in Biological Fluids

Determination of nicotine concentrations in biological fluids requires a sensitive and specific method, because concentrations of nicotine in smokers' blood are generally in the low nanogram per milliliter range and a number of metabolites are also present. Cotinine concentrations in blood are generally about tenfold greater than nicotine concentrations, and as a result, less sensitive analyti-

cal methodology may be acceptable. Methods with adequate sensitivity for determination of nicotine and cotinine in smokers' blood include gas chromatography (GC) (Curvall, Kazemi-Vala, Enzell 1982; Davis 1986; Feyerabend, Levitt, Russell 1975; Hengen and Hengen 1978; Jacob, Wilson, Benowitz 1981; Vereby, DePace, Mule 1982), radioimmunoassay (RIA) (Langone, Gjika, Van Vunakis 1973; Castro et al. 1979; Knight et al. 1985), enzyme-linked immunosorbent assay (ELISA) (Bjercke et al. 1986), high performance liquid chromatography (HPLC) (Machacek and Jiang 1986; Chien, Diana, Crooks, in press), and combined gas chromatograph-mass spectrometry (GC-MS) (Dow and Hall 1978; Gruenke et al. 1979; Jones et al. 1982; Daenens et al. 1985). For reasons of sensitivity, specificity, and economy, GC and RIA are the most frequently used methods. GC-MS is a highly sensitive and specific technique, but the expense has discouraged its routine use. HPLC is less sensitive than GC for nicotine and cotinine determination. Although recently reported methods (Machacek and Jiang 1986; Chien, Diana, Crooks, in press) appear to have adequate sensitivity for determining concentrations in plasma, relatively large sample volumes are required. Concentrations of nicotine and cotinine in urine are tenfold to hundredfold greater than concentrations in plasma or saliva (Jarvis et al. 1984), and a variety of chromatographic and immunoassay techniques meet sensitivity requirements.

The choice of a particular method depends on the biological fluid to be assayed; the need for sensitivity, precision, and accuracy; and economic considerations. Chromatographic methods, particularly those utilizing high-resolution capillary columns and specific detectors such as nitrogen-phosphorus detectors or a mass spectrometer, provide the greatest specificity. On the other hand, immunoassay techniques are operationally simpler, generally require smaller samples, and may be less expensive than chromatographic methods. A drawback to immunoassay methods is the potential for cross-reactivity of the antibody with metabolites or endogenous substances. There is generally a good correlation between results obtained by GC and RIA for plasma cotinine concentrations ($r=0.94$) (Gritz et al. 1981; Biber et al. 1987). In an interlaboratory comparison study (Biber et al. 1987), cotinine concentrations in smokers' urine measured by RIA were generally higher than concentrations determined by GC, whereas in nonsmokers' urine spiked with cotinine RIA and GC values were similar. These results suggest that nicotine metabolites cross-react with the antibody against cotinine, at least in some of the RIA methods.

Pharmacodynamics of Nicotine

General Considerations

This Section will focus on the relationship between nicotine levels in the body and their effects on behavior and physiological function

(pharmacodynamics). These data show how pharmacodynamic factors determine some of the consequences of cigarette smoking. Two issues are particularly relevant in understanding the pharmacodynamics of nicotine: a complex dose-response relationship and the level of tolerance that is either preexisting or is produced by administration of nicotine.

Dose-Response

The relationship between the dose of nicotine and the resulting response (dose-response relationship) is complex and varies with the specific response that is measured. In pharmacology textbooks, nicotine is commonly mentioned as an example of a drug which in low doses causes ganglionic stimulation and in high doses causes ganglionic blockade following brief stimulation (Comroe 1960). This type of effect pattern is referred to as "biphasic." Dose-response characteristics in functioning organisms (in vivo) are often biphasic as well, although the mechanisms are far more complex. For example, at very low doses, similar to those seen during cigarette smoking, cardiovascular effects appear to be mediated by the CNS, either through activation of chemoreceptor afferent pathways or by direct effects on the brain stem (Comroe 1960; Su 1982). The net result is sympathetic neural discharge with an increase in blood pressure and heart rate. At higher doses, nicotine may act directly on the peripheral nervous system, producing ganglionic stimulation and the release of adrenal catecholamines. With high doses or rapid administration, nicotine produces hypotension and slowing of heart rate, mediated either by peripheral vagal activation or by direct central depressor effects (Ingenito, Barrett, Procita 1972; Porsius and Van Zwieten 1978; Henningfield, Miyasato, Jasinski 1985).

Tolerance

A second pharmacologic issue of importance is development of tolerance; that is, after repeated doses, a given dose of a drug produces less effect or increasing doses are required to achieve a specified intensity of response. Functional or pharmacodynamic tolerance can be further defined as where a particular drug concentration at a receptor site (in humans approximated by the concentration in blood) produces less effect than it did after a prior exposure. Dispositional or pharmacokinetic tolerance refers to accelerated drug elimination as a mechanism for diminished effect after repeated doses of a drug. Behavioral tolerance refers to compensatory behaviors that reduce the impact of a drug to adversely affect performance. Such tolerance can occur following intermittent exposures to a drug such that there is minimal development of functional or dispositional tolerance.

Most studies of drug tolerance have focused on tolerance which develops as a drug is chronically administered. If the tolerance develops within one or two doses, it is referred to as acute tolerance or tachyphylaxis. If tolerance develops after more prolonged use, the tolerance is referred to as acquired or chronic tolerance. Individual differences in sensitivity to the first dose of a drug also frequently exist. Those individuals who exhibit a reduced response to a specified drug dose or require a greater dose to elicit a specified level of response are said to be tolerant to the drug. This form of tolerance is referred to as first-dose tolerance, drug sensitivity, or innate drug responsiveness. For sake of clarity, this Report will reserve the term tolerance to describe reduction in the response to nicotine during the course of or following a previous exposure and will use acute drug sensitivity to describe responsiveness to an initial dose.

Studies of tolerance to nicotine began in the late 19th century. In a series of studies of fundamental importance to the understanding of the nervous system, as well as to understanding the pharmacology of nicotine, Langley (1905) and Dixon and Lee (1912) studied the effects of repeated nicotine administration on a variety of animal species and on in vitro tissue preparations. Several findings emerged which have been widely verified and extended to other species and responses. These include: (1) With repeated dosing, responses diminished to nearly negligible levels; (2) After tolerance occurred, responsiveness could be restored by increasing the size of the dose; (3) After a few hours without nicotine, responsiveness was partially or fully restored.

After smoking a cigarette, people who have not smoked before ("naive smokers") usually experience a number of effects that become generally uncommon among experienced smokers. For example, retrospective reports by smokers indicate that initial exposure to tobacco smoke produced dizziness, nausea, vomiting, headaches, and dysphoria, effects that disappear with continued smoking and are rarely reported by chronic smokers (Russell 1976; Gritz 1980). Tolerance may also develop to toxic effects, such as nausea, vomiting, and pallor, during the course of nicotine poisoning, despite persistence of nicotine in the blood in extremely high concentrations (200 to 300 ng/mL) (Benowitz, Lake et al. 1987).

A systematic analysis of the various forms of tobacco smoke tolerance has not been carried out. There are a few studies comparing the effects elicited by an acute exposure to tobacco in nonsmokers and smokers. Clark and Rand (1968) studied the effect of smoking cigarettes of varying nicotine content on the knee-jerk reflex and reported that high-nicotine cigarettes suppressed this reflex to a greater degree than did low-nicotine cigarettes. This effect was more pronounced at each nicotine dose in nonsmokers and light smokers compared to heavy smokers. These findings suggested that

tolerance is due to altered sensitivity to nicotine. Tolerance to nicotine is not complete because even the heaviest smokers experience symptoms such as dizziness, nausea, and dysphoria when they suddenly increase their smoking rates (Danaher 1977). Evidence indicates that the majority of the psychological actions of tobacco smoke result from nicotine (Russell 1976; Chapter VII). Thus, most of the tolerance to effects of tobacco smoke that occurs following chronic tobacco use is due to the development of tolerance to nicotine.

Acute Sensitivity

Human Studies

Studies which have indicated that individuals differ in response to tobacco smoke or nicotine have used smokers as the experimental subjects. Consequently, whether individual differences are due to differences in acute sensitivity to nicotine that have persisted during chronic tobacco use or are due to differences in the development of tolerance is unknown.

Nesbitt (1973) and Jones (1986) noted that individual smokers differ with respect to the effects of smoking a standard cigarette on heart rate, but it is not clear from these studies whether these differences in responsiveness are due to differences in sensitivity to nicotine or to differences in the dose and kinetics of nicotine. Benowitz and colleagues (1982) observed individual differences in the effects of i.v. injections of nicotine on heart rate, blood pressure, and fingertip skin temperature. Differences were not explained by differences in blood levels, indicating differential sensitivity to nicotine.

Animal Studies

Studies using laboratory animals indicate that differences in acute sensitivity to nicotine exist. Inbred rat and mouse strains differ in sensitivity to the effects of nicotine on locomotor activity (Garg 1969; Battig et al. 1976; Schlatter and Battig 1979; Hatchell and Collins 1980; Marks, Burch, Collins 1983b). Mouse strains also differ in the direction of the effect (increased or decreased activity). The mouse strains that differ in sensitivity to the effects of injected nicotine on locomotor activity also differ in the magnitude of response to a standard dose of tobacco smoke (Baer, McClearn, Wilson 1980). Inbred mouse strains also differ in sensitivity to the effects of nicotine on body temperature, heart rate, and acoustic startle response (Marks, Burch, Collins 1983a; Marks et al. 1985, 1986), as well as in sensitivity to nicotine-induced seizures (Tepper, Wilson, Schlesinger 1979; Miner, Marks, Collins 1984, 1986). These findings indicate that genetic factors may influence the sensitivity of rats and

mice to the first dose of nicotine. The importance of genetically determined differences in human sensitivity to the effects of nicotine administered in tobacco smoke remains to be determined.

Mechanisms of Differences in Acute Sensitivity

Differences between inbred mouse and rat strains in sensitivity to the effects elicited by a single injected dose of nicotine do not appear to result from differences in rate of nicotine metabolism (Petersen, Norris, Thompson 1984) or from differences in brain nicotine concentration following intraperitoneal injection (Hatchell and Collins 1980; Rosecrans 1972; Rosecrans and Schechter 1972). Thus, rat and mouse strains differ in tissue sensitivity to the effects of nicotine. Differences among mouse strains in sensitivity to nicotine do not appear to be due to differences in the number or affinity of brain nicotine receptors that are measured via the binding of ³H-nicotine (Marks, Burch, Collins, 1983b). Mouse stocks that are more sensitive to nicotine-induced seizures do have greater numbers of hippocampal nicotine receptors that bind ¹²⁵I-bungarotoxin (BTX) (Miner, Marks, Collins 1984, 1986). Some of the differences in sensitivity to nicotine between genetically defined stocks of animals may be related to differences in the number of nicotine receptors in specific regions of the brain.

Tachyphylaxis (Acute Tolerance)

Human Studies

Systematic studies of tachyphylaxis or acute tolerance to effects of tobacco in nonsmokers have not been reported. There is evidence that tachyphylaxis does develop to effects of tobacco and nicotine in humans. Smokers frequently report that the first cigarette of the day is the best and that subsequent cigarettes are "tasteless" (Russell 1976; Henningfield 1984). Smoking a single standard cigarette after 24 hr of abstinence increases heart rate, whereas smoking an identical cigarette during the course of a normal day fails to change heart rate (West and Russell 1987). Fewer standard puffs were required to produce nausea at the beginning of the day (following 8 to 10 hr of tobacco abstinence) or from high-nicotine cigarettes than at the end of the day or from low-nicotine cigarettes (Henningfield 1984). Complete tolerance to nausea and vomiting developed over 8 hr in a woman in the course of an accidental nicotine poisoning, despite persistently toxic blood levels of nicotine (Benowitz, Lake et al. 1987). These findings suggest that tolerance which is lost and regained during short periods of abstinence from tobacco is tolerance to nicotine.

Tolerance develops very rapidly to several effects of nicotine. Rosenberg and colleagues (1980) studied the effects of i.v. nicotine

injections on arousal level, heart rate, and blood pressure. In these experiments, six healthy smokers, 21 to 35 years of age, received six series of nicotine injections spaced 30 min apart. Each series of injections consisted of 10 2- $\mu\text{g}/\text{kg}$ injections spaced 1 min apart. Subjects reported a pleasant sensation after the first series of injections, but this response was not observed thereafter. Heart rate and blood pressure values remained above baseline, but there was little increment with successive injections, despite nicotine blood level increases which were similar to those observed after the first series of injections. In contrast, skin temperature fell progressively during the period of nicotine dosing, gradually returning to baseline at the end of the study. These data indicated rapid development of tolerance to subjective effects and heart rate and blood pressure responses, but tolerance was not complete because heart rate and blood pressure remained above baseline. Henningfield (1984) also assessed subjective responses of human subjects after i.v. injections with nicotine at 10-min intervals. The subjective response of "liking" the effects of nicotine was lost after five or six injections. Benowitz and coworkers (1982) studied the effect of a 30-min infusion of nicotine at a rate of 1 to 2 $\mu\text{g}/\text{kg}/\text{min}$. Shortly after initiation of infusion, heart rate and blood pressure increased, but the increase did not continue even though plasma nicotine concentrations continued to rise during the continuous infusion. Maximal cardiovascular changes were seen within 5 to 10 min, whereas maximal plasma nicotine levels were not reached until 30 min. These findings indicate that tachyphylaxis to the effects of nicotine may develop in humans within 5 to 10 min, the time required to smoke one cigarette. In contrast to heart rate, skin temperature (reflecting cutaneous vascular tone) declined and rose in association with changes in blood nicotine concentrations, showing no evidence of tolerance.

The above studies indicate rapid development of tolerance to some (but not all) actions of nicotine in people. These studies were performed with cigarette smokers who had abstained from smoking the night before the study. Since significant quantities of nicotine persist in the body even after overnight abstinence, there is probably some persistence of tolerance. Experimental data supporting this conclusion were obtained in a study of cardiovascular responses to infused nicotine in smokers following either an overnight or 7-day tobacco abstinence (Lee, Benowitz, Jacob 1987). Heart rate and blood pressure responses were significantly greater after more prolonged abstinence. However, within 60 to 90 min, the blood concentration-effect relationship in subjects after brief abstinence approximated that observed after prolonged abstinence. Thus, a significant level of tolerance persists throughout the daily smoking cycle, but is lost with prolonged abstinence. Tolerance, at least after abstinence for one week, is rapidly reestablished with subsequent exposure.

Animal Studies

Many studies demonstrate that acute tolerance or tachyphylaxis develops very quickly to actions of nicotine. Barrass and coworkers (1969) demonstrated that pretreatment of mice with a single i.v. dose (0.8 mg/kg) of nicotine resulted in an increase in the LD₅₀ (dose which is lethal to 50 percent of animals) for nicotine. Maximal protection was seen 5 min after the injection, but this protection diminished steadily over the next hour. Tachyphylaxis develops to the effects of nicotine on locomotor activity. Stolerman, Bunker, and Jarvik (1974) noted that pretreating rats with a 0.75-mg/kg dose of nicotine 2 hr before challenge doses of nicotine (0.25 to 4.0 mg/kg) resulted in a shift of the nicotine dose-response curves, indicating reduced sensitivity. The ED₅₀ values (doses that are effective in producing the measured response in 50 percent of animals) for nicotine-induced decreases in locomotor activity were nearly 2.4-fold greater in nicotine-pretreated rats than in saline-pretreated animals. Nicotine pretreatment also results in tachyphylaxis to the effects of nicotine on body temperature (hypothermia) in cats (Hall 1972), water-reinforced operant responding in rats (Stitzer, Morrison, Domino 1970), discharge of lateral geniculate neurons of cats (Roppolo, Kawamura, Domino 1970), repolarization of sartorius muscle in frogs (Hancock and Henderson 1972), blood pressure elevation in rats (Wenzel, Azmeh, Clark 1971), contraction of aortic strips in rabbits (Shibata, Hattori, Sanders 1971), respiratory stimulation in cats (McCarthy and Borison 1972), and gastrointestinal contraction in squid (Wood 1969) and guinea pigs (Hobbiger, Mitchelson, Rand 1969). More recent studies have demonstrated that pretreatment with as little as one dose of nicotine will attenuate nicotine-induced elevations of plasma corticosterone (Balfour 1980) and adrenocorticotrophic hormone (ACTH) (Sharp and Beyer 1986) levels in rats (see also Chapter III).

The interval between the pretreatment and challenge doses of nicotine is a critical factor that determines whether tachyphylaxis is observed. Aceto and coworkers (1986) examined the effect of i.v. nicotine infusion on heart rate and blood pressure in the rat. Tolerance did not develop when the interval between pretreatment and challenge doses was 30 min; marked tolerance was detected when the interval was reduced to 1 min. However, Stolerman, Fink, and Jarvik (1973) observed that after a single intraperitoneal dose of nicotine to rats, acute tolerance to a second dose did not become maximal until 2 hr after the initial injection.

Mechanisms of Tachyphylaxis

Although tachyphylaxis has been described for a wide variety of nicotine's effects, very little is known about mechanisms. A nicotine

metabolite may play a role in the development of tachyphylaxis. Barrass and colleagues (1969) argued that nicotine metabolites may block nicotine receptors and thereby antagonize nicotine's lethal effects. This argument was made because pretreatment with nicotine-N'-oxide protected mice from the lethal effects of large doses of nicotine. LD₅₀ values were increased approximately ninefold by pretreatment with nicotine-N'-oxide. These authors hypothesized that this protection may involve conversion of nicotine-N'-oxide to hydroxynicotine. Their results indicated that injection of a reduction product of cotinine, believed to be hydroxynicotine, gave immediate protection, whereas maximum protection was not seen until 40 min after injection of nicotine-N'-oxide. Thus it appears that metabolism, possibly to hydroxynicotine, is required for the protective action of nicotine-N'-oxide.

Another hypothesis is that tachyphylaxis is the result of desensitization of nicotine receptors. Desensitization of the receptor involves a conformational change that results in increased affinity of the nicotinic receptor for agonists coupled with decreased ability of the receptor to transport ions (Weiland et al. 1977; Sakmann, Patlak, Neher 1980; Boyd and Cohen 1984). Desensitization of nicotinic receptors at the motor end-plate was first described by Katz and Thesleff (1957) and has since been studied by a large number of investigators, using either skeletal muscle or the electric organs of the eel, *Torpedo californica*. Although tachyphylaxis has been commonly suggested as being due to desensitization of brain nicotinic receptors, the role of desensitization in tachyphylaxis to specific behavioral effects of nicotine has not been studied. This is because concentrations of nicotinic receptors in specific areas of the brain corresponding to the behavioral effects being measured are not high enough to use available methods.

Chronic Tolerance

Human Studies

Chronic tolerance to tobacco and nicotine has not been studied systematically in human subjects, but it is clear, as noted previously, that some tolerance does develop. Tolerance is not complete; symptoms of nicotine toxicity such as nausea appear when smokers increase their normal tobacco consumption by as little as 50 percent (Danaher 1977).

These findings are consistent with the observations that smokers increase their tobacco consumption and intake of nicotine with experience. Such escalating dose patterns may be observed for several years after initiation of either cigarette smoking or smokeless tobacco use. Cigarette smokers may achieve such increases by augmenting the number of cigarettes smoked and by increasing the amount of nicotine extracted from each cigarette. For users of

smokeless tobacco, switching to products with greater nicotine delivery may also contribute to nicotine dose escalation (US DHHS 1986).

Animal Studies

Animal studies have proved useful in establishing the actual development of tolerance to nicotine, the magnitude of such tolerance, and mechanisms that underlie this tolerance. The majority of these studies have used the rat and mouse as experimental subjects.

Most of the chronic tolerance studies using the rat have focused on the effects of nicotine on locomotor activity. Depression of locomotor activity typically occurs following the injection of nicotine in doses exceeding 0.2 mg/kg in drug-naive rats. Tolerance to this depression develops following chronic treatment (Keenan and Johnson 1972; Stolerman, Fink, Jarvik 1973; Stolerman, Bunker, Jarvik 1974). The magnitude of this tolerance is influenced by the dose and dosing interval. Tolerance persists for greater than 90 days when nicotine is injected chronically. Tolerance to the effects of injected nicotine on depression of locomotor activity could also be produced with nicotine administered in the rats' drinking water or through subcutaneously implanted reservoirs (Stolerman, Fink, Jarvik 1973).

Under certain experimental conditions, rats treated chronically with nicotine exhibit an increase in locomotor activity following nicotine challenge (Morrison and Stephenson 1972; BaA5ttig et al. 1976; Clarke and Kumar 1983a,b). A careful analysis of the response to an acute challenge dose of nicotine demonstrated that soon after the first dose of nicotine, depressed locomotor activity was observed; after 40 min or more, increased locomotor activity became apparent (Clarke and Kumar 1983b). Chronically injected rats exhibited this enhanced activity progressively earlier postinjection. More recently, Ksir and others (1985, 1987) demonstrated that chronic nicotine injections may result in enhanced locomotor activity immediately after nicotine injection if the rats were acclimated to the test apparatus for 1 hr before nicotine injection. These findings indicate that in the rat, tolerance develops to the depressant effects of nicotine and that this tolerance uncovers a latent stimulatory action.

If mice are injected chronically with nicotine, tolerance develops to the locomotor depressant effects elicited by a challenge dose of nicotine (Hatchell and Collins 1977). The degree and rate of development of tolerance appear to be influenced by the sex, as well as the strain, of the animals. Tolerance development has been studied by continuously infusing mice of several inbred strains with nicotine and assessing tolerance by measuring locomotor activity, body temperature, respiratory rate, heart rate, and acoustic startle response following nicotine challenge. Such studies have demonstrated that: (1) Tolerance to nicotine increases with the nicotine

infusion dose (Marks, Burch, Collins 1983a); (2) Tolerance is specific for nicotinic cholinergic agonists in that nicotine-infused animals are not cross-tolerant to the muscarinic cholinergic agonist oxotremorine (Marks and Collins 1985); (3) Maximal tolerance is attained within 4 days following the initiation of infusion and is lost within 8 days following the cessation of infusion (Marks, Stitzel, Collins 1985); (4) Tolerance development varies between inbred mouse strains, with some strains exhibiting marked tolerance and other strains showing very little (Marks, Romm et al. 1986); and (5) Mouse strains that fail to develop tolerance to nicotine are also relatively insensitive to the effects elicited by an acute injection of nicotine (Marks, Stitzel, Collins 1986). More recently these investigators compared the effects of continuous and pulse infusions of nicotine on tolerance development (Marks, Stitzel, Collins 1987). Pulse infusion was used to simulate the conditions obtained when tobacco is smoked. Although the total dose infused was the same in continuously infused and pulse-infused animals, marked differences in tolerance were seen. The pulse-infused animals exhibited a greater degree of tolerance. The degree of tolerance was most correlated with peak nicotine concentrations.

Chronic nicotine administration results in tolerance to a number of other nicotinic effects. Tolerance develops to depression of operant responding elicited by high doses of nicotine, such that after sufficient chronic treatment, enhanced rather than depressed operant responding is seen (Clarke and Kumar 1983c; Hendry and Rosecrans 1982). Attenuation of the effects of nicotine on electroencephalogram (EEG) activity is seen in the rat following chronic injection (Hubbard and Gohd 1975). These altered EEG responses paralleled the development of tolerance to behavioral effects described by these authors as "arousal." In contrast to the findings of Hubbard and Gohd (1975), other studies indicate that chronic tolerance does not develop to the behavioral stimulation effect of nicotine (Battig et al. 1976; Morrison and Stephenson 1972; Clarke and Kumar 1983a,c). Likewise, little or no tolerance to nicotine-induced prostration after i.v. administration was observed after chronic exposure in rats (Abood et al. 1981, 1984).

In addition, tolerance has been reported to develop to nicotine-induced increases in plasma corticosterone, but not adrenal catecholamine release in rats (Balfour 1980; Van Loon et al. 1987). Anderson and colleagues (1985) studied the effects of chronic exposure to cigarette smoke on neuroendocrine function of the rat hypothalamus. These researchers observed that chronic exposure to cigarette smoke over a period of 9 days did not result in tolerance to the ability of acute intermittent exposure to cigarette smoke to reduce serum levels of prolactin, luteinizing hormone, and follicle stimulating hormone.

Mechanisms of Chronic Tolerance

Chronic tolerance to drugs may be due to an increase in the rate of drug metabolism or to a decrease in sensitivity of the tissue to the drug. Considerable differences exist among humans in the rate of nicotine metabolism (Benowitz et al. 1982). Metabolism is faster (shorter half-life) in smokers than in nonsmokers (Schievelbein et al. 1978; Kyerematen et al. 1982; Kyerematen, Dvorchik, Vesell 1983). The contribution of enhanced nicotine metabolism to the development of nicotine tolerance in humans is unclear. Studies of rats which clearly demonstrate that chronic nicotine treatment results in tolerance to nicotine also indicate that chronic nicotine administration does not increase the rate of nicotine metabolism in rats (Takeuchi, Kurogochi, Yamaoka 1954) or mice (Hatchell and Collins 1977; Marks, Burch, Collins 1983b). These findings indicate that tolerance to nicotine primarily involves reduced sensitivity of target tissues.

Chronic tolerance to nicotine may be due to alterations in brain nicotinic receptors (see Chapter III for further discussion of nicotine receptors). At least two types of nicotinic receptors exist in rodent brain (Marks and Collins 1982). One of these receptor types may be measured with ^3H -nicotine or ^3H -acetylcholine (^3H -ACh) (Marks, Stitzel et al. 1986; Martino-Barrows and Keller 1987), while the other type may be measured with ^{125}I -bungarotoxin (BTX). The nicotine-binding site has higher affinity for nicotine than does the BTX site (Marks and Collins 1982). Chronic nicotine injection, once or twice daily for approximately 7 days, increased the number of ^3H -nicotine/ ^3H -ACh-binding sites in the brain (Ksir et al. 1985, 1987; Morrow, Loy, Creese 1985; Schwartz and Kellar 1983, 1985). This increase in nicotine-binding sites appeared to correlate with the emergence of nicotine-induced increases in locomotor activity in the rat. Studies of tolerance to nicotine in one inbred mouse strain (DBA) also demonstrated that chronic nicotine treatment elicits an increase in the number of brain nicotinic receptors as measured with both ^3H -nicotine and BTX as the ligands (Marks, Burch, Collins 1983a; Marks and Collins 1985; Marks et al. 1985, 1986; Marks, Stitzel, Collins 1985, 1986, 1987). These studies have also shown that the number of ^3H -nicotine-binding sites increases at lower doses of nicotine than do the BTX-binding sites. An increase in ^3H -nicotine binding (Marks, Burch, Collins 1983a) parallels development of tolerance to various responses during chronic infusion. In chronically infused DBA mice, tolerance acquisition and disappearance parallel the up-regulation and return to control, respectively, of brain ^3H -nicotine binding (Marks, Stitzel, Collins 1985). These findings suggest that the increase in ^3H -nicotine binding is related to the development of tolerance to nicotine. However, further studies indicate that factors other than receptor number must also be considered, because mouse

strains that do not develop tolerance to nicotine also demonstrate up-regulation of nicotinic receptors following chronic infusion (Marks et al. 1986; Marks, Stitzel, Collins 1986).

That chronic nicotine treatment results in a decrease in response to the drug (tolerance) and an increase in the number of nicotinic receptors was an unexpected finding. Marks, Burch, and Collins (1983a) and Schwartz and Kellar (1985) have suggested that chronic nicotine treatment results in chronic desensitization of nicotinic receptors. Chronic desensitization of the nicotinic receptor is comparable to chronic treatment with an antagonist and could be the stimulus for up-regulation of the receptors. According to this hypothesis, there is an increase in number of brain nicotinic receptors but a decrease in the absolute number of "activatable" (nondesensitized) receptors. This would result in a decreased response to nicotine (tolerance). Marks and coworkers suggest that inbred mouse strains failing to exhibit tolerance to nicotine, under the procedures used by these investigators, have brain nicotinic receptors that resensitize more rapidly than do those strains that do exhibit tolerance.

By treating rats chronically with the acetylcholinesterase inhibitor disulfoton, Costa and Murphy (1983) have found a decrease in rat brain ³H-nicotine binding. Disulfoton-treated rats were also tolerant to the antinociceptive effects of nicotine. Thus, tolerance to nicotine effects may be seen when the number of nicotinic receptors is increased or decreased by chronic drug treatment. The observation that tolerance to at least one effect of nicotine can be obtained by a technique that decreases brain nicotinic receptor numbers supports the idea that chronic nicotine treatment results in an increase in the total number of receptors but a decrease in those that may be activated by nicotine; that is, a high fraction of the up-regulated receptors are desensitized.

In contrast to the studies reviewed above, some investigators have found no change in the number or affinity of ³H-nicotine-binding sites in the brains of rats chronically exposed to nicotine (Abood et al. 1984; Benwell and Balfour 1985).

Other potential neurochemical explanations for tolerance to nicotine have been considered. Several reports (Westfall 1974; Giorguieff et al. 1977; Arqueros, Naquira, Zunino 1978; Giorguieff-Chesselet et al. 1979) indicate that nicotine stimulates dopamine release in vitro, and a recent study demonstrated that nicotinic agonists are less effective in stimulating dopamine release in slices of striatum obtained from rats that had been chronically treated with the nicotinic agonist dimethylphenylpiperazinium (DMPP) (Westfall and Perry 1986). These findings are consistent with the idea that chronic nicotinic agonist treatment results in a decrease in the absolute number of receptors that can be activated.

Pharmacodynamics of Nicotine and Cigarette Smoking

As the foregoing review has shown, the intensity of nicotine's effects is related to the dose given, the time since the last dose, and the level of preexisting or acquired tolerance. Since nicotine can produce effects that lead to further use (reinforcing effects) (Henningfield and Goldberg 1983) and can also produce effects that limit use (aversive effects, usually at higher dose levels) (Danaher 1977), the strength of the effect of a given dose can determine whether more or less nicotine will be subsequently taken. Thus, factors such as tolerance can affect the manner in which nicotine controls behavior (Chapter IV). Similarly, an individual's ability to develop tolerance to the toxic actions may be critical in determining whether smoking will occur and, if smoking is initiated, whether there will be an increase in the number of cigarettes consumed each day.

Pharmacodynamic considerations may help explain the pattern of cigarette smoking throughout the day. Intervals between smoking cigarettes may be determined at least in part by the time required for tolerance to disappear. With regular smoking there is accumulation of nicotine in the body resulting in a greater level of tolerance. Transiently high brain levels of nicotine following smoking individual cigarettes may partially overcome tolerance. But the effects of individual cigarettes tend to lessen throughout the day. Overnight abstinence allows considerable resensitization to effects of nicotine, and the daily smoking cycle begins again.

Pharmacodynamic observations with i.v. dosing of nicotine explain the pattern of cardiovascular changes observed in cigarette smokers. That brief infusions of nicotine increase heart rate to a maximum suggests that heart rate will increase most with the first few cigarettes of the day, but subsequently will not vary in relation to the amount of nicotine consumed. That only partial tolerance develops to heart rate acceleration due to nicotine suggests that effects on heart rate may persist as long as significant levels of nicotine persist, including overnight. These predictions were confirmed in a study in which volunteer cigarette smokers smoked either high- or low-yield nonfilter research cigarettes or abstained from smoking (Benowitz, Kuyt, Jacob 1984). Full compensation for the low-yield research cigarettes, which contained only small amounts of nicotine, was impossible. Resultant nicotine blood levels were different by fourfold. As predicted, heart rate (assessed by continuous ambulatory electrocardiogram (EKG) monitoring) increased in the morning--more on smoking than nonsmoking days--and the increase occurred with the first few cigarettes of the day. Subsequently, heart rate followed a normal circadian pattern, but was always higher during smoking than during abstinence. Also, as predicted, heart rate was no different during the smoking of low-

yield or high-yield cigarettes, despite the fourfold difference in blood nicotine concentration.

Pharmacodynamic aspects of the actions of nicotine may explain in part how cigarette smoking causes coronary heart disease (US DHHS 1983). As noted before, because of the accumulation of nicotine and its dose-response characteristics, heart rate is increased during cigarette smoking for 24 hr a day. Plasma catecholamine concentrations and urinary catecholamine excretion remain increased as well (Benowitz 1986c), consistent with the theory that cigarette smoking produces sympathetic neural activation 24 hr each day. Persistent sympathetic activation could result in the following effects: (1) Alteration in lipid metabolism, resulting in a more atherogenic lipid profile; (2) Promotion of platelet aggregation and hypercoagulability; (3) Induction of vasoconstriction and coronary spasm; and (4) Increased heart rate and myocardial contractility, thereby an increase in the oxygen demands of the heart and of circulating catecholamines, which can promote cardiac arrhythmias. These factors could accelerate atherosclerosis and contribute to acute myocardial infarction in a person with preexisting coronary atherosclerosis (Benowitz 1986a) (see also Appendix B). There is no apparent correlation between acute coronary events and the time at which a person smokes a cigarette, perhaps because of the persistent effects of nicotine throughout the day.

Constituents of Tobacco Smoke Other Than Nicotine With Potential Behavioral Effects

Tobacco smoke contains more than 4,000 constituents, many of which may have biological activity (US DHHS 1983). Although nicotine is the major pharmacologic factor which determines the use of tobacco, other constituents may also be involved. The behavioral effects of tobacco constituents other than nicotine are described in the Section below and in Chapter IV. This Section focuses more on the chemicals that may be involved, whereas Chapter IV focuses more on cigarette smoking behavior.

Minor Tobacco Alkaloids

Most of the research on the minor tobacco alkaloids has been directed to determining physiological effects, such as the effect on blood pressure and other cardiovascular responses and toxicological effects, rather than the potential for behavioral effects. The pharmacologic effects of alkaloids of the nicotine group have been discussed by Bovet and Bovet-Nitti (1948) and Clark, Rand, and Vanov (1965). Nornicotine and anabasine were found to have qualitatively similar actions but to be less potent than nicotine. Larson and Haag (1943)

reported that the potency of nornicotine as determined by effects on blood pressure in dogs was about one-twelfth that of nicotine.

Nicotine analogs have been studied for discriminative stimulus effects by using animal models (Chance et al. 1978) (see also Chapter IV). The only chemical shown to produce a positive response in that test system was 3-methylpyridylpyrrolidine. Recent research has focused on binding at specific brain receptor sites. Martin and coworkers compared binding characteristics of nicotine-related compounds (Martin et al. 1986; Sloan et al. 1985). Lobeline, anabesine, and cytisine were evaluated for effects on heart rate, blood pressure, respiration rate, minute volume, and tidal volume (Sloan et al. 1987). Lobeline and anabesine bound to low-affinity sites in the brain, whereas cytisine bound only at a high-affinity site. The binding data are consistent with the pharmacologic data, indicating that lobeline and anabesine have different pharmacologic actions than cytisine. Kanne and others (1986) and Abood and Grassi (1986) evaluated two nicotine analogs, including a new radioligand, to study brain nicotinic receptors. Kachur and others (1986) studied the pharmacologic effects of a bridged-nicotine analog (methylene bridge between the methyl of the pyrrolidine ring and the *a*-position of the pyridine ring). The magnitude of pressor effect depended on the particular enantiomer and dosage. These results emphasize that compounds other than nicotine may act at the nicotine receptors; however, there may be subpopulations of receptors to which different agonists and antagonists bind (Chapter III).

N-Methylated derivatives of nicotine, including nicotine isomethonium ion (N-methylnicotinium ion, NMN), have been shown to have pressor and neuromuscular effects in some species (Shimamoto et al. 1958). Nicotine isomethonium ion was first reported to be a metabolite of nicotine present in smokers' urine by McKennis and coworkers in the 1960s and its presence in smokers' urine has been recently confirmed (Neurath et al. 1987). Recently Crooks and coworkers (Cundy, Godin, Crooks 1985) have shown that only the (R)-isomer of nicotine is converted to nicotine isomethonium ion in vitro in guinea pig tissue homogenates or in vivo in guinea pigs. Consequently, it is uncertain as to whether the nicotine isomethonium ion present in smokers' urine arrives from the small amount of (R)-nicotine present in tobacco smoke, or whether the human enzyme systems have different specifications than the guinea pig enzymes. Because little if any nicotine isomethonium ion penetrates the blood-brain barrier (Pool 1987; Aceto et al. 1983), it would appear that this metabolite could have behavioral actions only if it were formed in the CNS. These findings emphasize the complexity of the pharmacology of nicotine-related compounds. It can be concluded from research on these compounds that some do bind to specific brain receptors and may result in centrally mediated physiological changes. However,

there is inadequate evidence to date that any of these compounds produces either aversive or rewarding effects in human smokers.

“Tar” and Selected Constituents of Tobacco Smoke Which Contribute to Taste and Aroma

“Tar” is used to describe the dry particulate matter without the nicotine in tobacco smoke (Pillsbury et al. 1969). The possible role of tar in the maintenance of the cigarette smoking habit has been considered. Goldfarb and coworkers (1976) studied the effects of the tar content (determined by cigarette smoking machine testing) on the subjective reactions to cigarette smoking. Ratings of strength were not related to the tar index of the cigarettes. The results were interpreted as indicating that tar did not have a role in the maintenance of cigarette smoking behavior. In a later study, Sutton and coworkers (1982) found that when nicotine yield was held constant, smokers of lower-tar cigarettes puffed more smoke and had higher drug plasma levels. These results suggested that smokers were compensating for reduced delivery of tar by inhaling a greater volume of smoke. Because these two studies used different experimental designs, it is difficult to draw a conclusion as to the role of tar in relation to smoking behavior. However, based on knowledge about the taste and aroma constituents of cigarette smoke, it is likely that some of the chemicals in the tar fraction contribute to tobacco use, if only by providing distinct sensory stimuli (Chapter VI). Consistent with this possibility, minimal levels of tar are held by tobacco manufacturers to be important to the taste characteristics of tobacco smoke.

Several thousand compounds have been isolated from tobacco and tobacco smoke (Dube and Green 1982), and many of these may be biologically active (IARC 1986). The precursors to the carotenoids and diterpenoids, selected nitrogenous and sulfur constituents, waxes and lipids, and phenolics and acids contribute to the taste and aroma of tobacco (Enzell and Wahlberg 1980; Heckman et al. 1981; Davis, Stevens, Jurd 1976). A number of the isoprenoid compounds that influence the taste and aroma of smoke may be formed by sequential oxidation, rearrangement, and reduction reactions (Davis, Stevens, Jurd 1976). Enzell and Wahlberg (1980) described several norisoprenoid compounds which are derived from the cyclic carotenoids and are important to smoke aroma. The particular taste and aroma of a cigarette can be influenced by the selection of the grade (quality and leaf position on the plant) and type of tobacco used in the blend.

Taste and smell receptors in the pharynx, larynx, and nose provide the first sensory input to the smoker as he or she lights up, an experience which is generally perceived as pleasurable (Rose et al. 1985). The taste and smell of tobacco smoke may be important

reinforcers for tobacco smoking (Jarvik 1977)--at least following repeated association with the reinforcing effects of nicotine administration (Chapter VI). By such behavioral conditioning, sensory cues provided by tar and flavor additives could come to control the tobacco-consuming behavior of the tobacco user. Changes in smoking patterns when brands are switched and brand selection may be a response in part to the particular flavor and aroma of the product (Thornton 1978).

Carbon Monoxide

The mainstream and sidestream carbon monoxide (CO) deliveries of cigarettes are influenced by cigarette design and puffing characteristics of the smokers. Depending upon these factors, the mainstream delivery usually ranges from 10 to 20 mg/cigarette. In a study of 29,000 blood donors in 18 locations around the United States, smokers were found to have median carboxyhemoglobin (COHb) levels ranging from 3.2 to 6.2 percent (Stewart et al. 1974). Anderson, Rivera, and Bright (1977) found the COHb levels in 50 smokers to vary from 3.9 to 14.0 percent, with the mean of 8.1 percent. The mean increment in COHb immediately after smoking 1 cigarette was 0.64 percent. COHb levels gradually decrease in blood after cessation of smoking. Carbon monoxide is eliminated in expired air. The rate of elimination depends on pulmonary blood flow and ventilation. The half-life of COHb is 2 to 4 hr during daytime hours, but as COHb is related to the level of exercise, the half-life may be as long as 8 hr during sleep (Wald et al. 1975). For these reasons, many smokers awaken in the morning with substantial levels of COHb, despite not smoking overnight (Benowitz, Kuyt, Jacob 1982). Persons smoking cigarettes with lower nicotine and CO yields have only slightly lower levels of COHb when compared with those smoking higher-yield products (Wald et al. 1980, 1981; Sutton et al. 1982; Hill, Haley, Wynder 1983; Benowitz, Jacob, Yu et al. 1986).

Benowitz and colleagues (1986) studied tar, nicotine, and CO exposure in smokers switched from their usual brand to low-, high-, and ultra-low-yield cigarettes. This study indicated that there were no differences in exposure comparing low- and high-yield, but tar and nicotine exposure were reduced by about 50 percent and CO by 36 percent while smoking ultra-low-yield cigarettes. Switching from a high to lower yield cigarette does not significantly reduce blood COHb although switching to ultra low cigarettes has been shown to lead to a significant reduction.

The toxic effects of high CO levels are well documented (US DHHS 1983). Some studies have tried to determine whether CO levels in the blood similar to those observed in smokers can affect behavior. Beard and Wertheim (1967) and Wright, Randell, and Shephard (1973) reported performance decrements with COHb levels below 5.0

percent; however, Guillerman, Radziszewski, and Caille (1978) found no psychomotor performance effects at COHb levels of 7 and 11 percent. Thus, the data are inconclusive with regard to the possible influence of CO on psychomotor performance at levels normally encountered in smokers.

Acetaldehyde and Other Smoke Constituents

Acetaldehyde is a major constituent of tobacco smoke, with mainstream smoke levels in commercial cigarettes ranging from 0.5 to 1.2 mg/cigarette (IARC 1986). The delivery of volatile aldehydes is influenced by cigarette design, with reductions achieved by specific filtration and air dilution techniques. Yields over 5.9 mg have been reported for large cigars (Hoffmann and Wynder 1977). Acetaldehyde is the primary metabolite of ethanol, and its toxic potency is 20 to 30 times that of ethanol. Acetaldehyde has been suggested to have an adverse effect on the heart (James et al. 1970). Acetaldehyde and acrolein, another important aldehyde in the gas phase of cigarette smoke, activate the sympathetic nervous system (Egle and Hudgins 1974). Acetaldehyde, by releasing norepinephrine, results in a pressor effect (Kirpekar and Furchgott 1972; Green and Egle 1983). Depressor effects occur at high doses of the aldehydes in guanethidine-pretreated hypertensive rats. Frecker (1983) indicated that condensation products of acetaldehyde may be active on endogenous opioid systems. Torreilles, Guerin, and Previero (1985) reviewed the synthesis and biological properties of beta-carbolines, the condensation products of tryptophan and indole alkylamines with aldehydes. Beta-carbolines occur as plant constituents, including minor constituents in tobacco. For example, harman (1-methyl- β -carboline) has been identified in tobacco and tobacco smoke (Snook and Chortyk 1984). Carbolines from other plant species have been used as hallucinogens. The research conducted to date indicates a potential pharmacologic effect of the aldehydes, especially with regard to cardiovascular physiology; however, the evidence is inadequate to determine if these volatile smoke constituents in the doses delivered in tobacco smoke contribute to the behavioral effects of cigarette smoking.

Summary and Conclusions

1. All tobacco products contain substantial amounts of nicotine and other alkaloids. Tobaccos from low-yield and high-yield cigarettes contain similar amounts of nicotine.
2. Nicotine is absorbed readily from tobacco smoke in the lungs and from smokeless tobacco in the mouth or nose. Levels of nicotine in the blood are similar in people using different forms of tobacco. With regular use, levels of nicotine accumulate in

the body during the day and persist overnight. Thus, daily tobacco users are exposed to the effects of nicotine for 24 hr each day.

3. Nicotine that enters the blood is rapidly distributed to the brain. As a result, effects of nicotine on the central nervous system occur rapidly after a puff of cigarette smoke or after absorption of nicotine from other routes of administration.
4. Acute and chronic tolerance develops to many effects of nicotine. Such tolerance is consistent with reports that initial use of tobacco products, such as in adolescents first beginning to smoke, is usually accompanied by a number of unpleasant symptoms which disappear following chronic tobacco use.

References

- ABOOD, L.G., GRASSI, S. [³H]Methylcarbamylocholine, a new radioligand for studying brain nicotinic receptors. *Biochemical Pharmacology* 35(23):4199-4202, December 1, 1986.
- ABOOD, L.G., GRASSI, S., COSTANZO, M., JUNIG, J. Behavioral and biochemical studies in rats after chronic exposure to nicotine. In: Sharp, C.W. (ed.) *Mechanisms of Tolerance and Dependence*, NIDA Monograph 54. U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. DHHS Publication No. (ADM) 84-1330, 1984, pp. 348-355.
- ABOOD, L.G., REYNOLDS, D.T., BOOTH, H., BIDLACK, J.M. Sites and mechanisms for nicotine's action in the brain. *Neuroscience Biobehavioral Reviews* 5(4):479-486, Winter 1981.
- ACETO, M.D., AWAYA, H., MARTIN, B.R., MAY, E.L. Antinociceptive action of nicotine and its methiodide derivatives in mice and rats. *British Journal of Pharmacology* 79(4):869-876, August 1983.
- ANDERSON, W.H., RIVERA, C., BRIGHT, M. Carboxyhemoglobin blood levels after smoking one cigarette in relation to puff profile. In: *1975 Symposium Nicotine and Carbon Monoxide, Proceedings-I*, University of Kentucky, Lexington, Kentucky, June 1977, pp. 130-136.
- ANDERSSON, K., ENEROTH, P., FUXE, K., MASCAGNI, F., AGNATI, L.F. Effects of chronic exposure to cigarette smoke on amine levels and turnover in various hypothalamic catecholamine nerve terminal systems and on the secretion of pituitary hormones in the male rat. *Neuroendocrinology* 41(6):462-466, December 1985.
- ARMITAGE, A.K., DOLLERY, C.T., GEORGE, C.F., HOUSEMAN, T.H., LEWIS, P.J., TURNER, D.M. Absorption and metabolism of nicotine from cigarettes. *British Medical Journal* 4(5992):313-316, November 8, 1975.
- ARMITAGE, A.K., DOLLERY, C.T., HOUSEMAN, T.H., KOHNER, E.M., LEWIS, P.J., TURNER, D.M. Absorption of nicotine from small cigars. *Clinical Pharmacology and Therapeutics* 23(2):143-150, February 1978.
- ARMITAGE, A.K., TURNER, D.M. Absorption of nicotine in cigarette and cigar smoke. *Nature* 226(5252):1231-1232, June 27, 1970.
- ARQUEROS, L., NAQUIRA, D., ZUNINO, E. Nicotine-induced release of catecholamines from rat hippocampus and striatum. *Biochemical Pharmacology* 27(23):2667-2674, 1978.
- BAER, D.S., McCLEARN, G.E., WILSON, J.R. Effects of chronic administration of tobacco smoke to mice: Behavioral and metabolic measures. *Psychopharmacology* 67:131-137, 1980.
- BALFOUR, D.J.K. Studies on the biochemical and behavioral effects of oral nicotine. *Archives Internationales de Pharmacodynamie et de Therapie* 245(1):245:95-103, 1980.
- BARRASS, B.C., BLACKBURN, J.W., BRIMBLECOMBE, R.W., RICH, P. Modification of nicotine toxicity by pretreatment with different drugs. *Biochemical Pharmacology* 18(9):2145-2152, September 1969.
- BATTIG, K., DRISCOLL, P., SCHLATTER, J., USTER, H.J. Effect of nicotine on the exploratory locomotion patterns of female Roman high- and low-avoidance rats. *Pharmacology Biochemistry and Behavior* 4:435-439, April 1976.
- BEARD, R.R., WERTHEIM, G.A. Behavioral impairment associated with small doses of carbon monoxide. *American Journal of Public Health* 57(1):2012-2022, November 1967.
- BECKETT, A.H., GORROD, J.W., JENNER, P. Absorption of (-)-nicotine-1'-N-oxide in man and its reduction in the gastrointestinal tract, (Letter). *Journal of Pharmacy and Pharmacology* 22(9):722-723, September 1970.

- BECKETT, A.H., GORROD, J.W., JENNER, P. The analysis of nicotine-1'-N-oxide in urine, in the presence of nicotine and cotinine, and its application to the study of in vivo nicotine metabolism in man. *Journal of Pharmacy and Pharmacology* 23(Supplement):55S-61S, December 1971a.
- BECKETT, A.H., GORROD, J.W., JENNER, P. The effect of smoking on nicotine metabolism in vivo in man. *Journal of Pharmacy and Pharmacology* 23(Supplement):62S-67S, December 1971b.
- BENOWITZ, N.L. Clinical pharmacology of nicotine. *Annual Review of Medicine* 37:21-32, 1986a.
- BENOWITZ, N.L. Human pharmacology of nicotine. In: Cappell, H.D. et al. (eds.) *Research Advances in Alcohol and Drug Problems*, Volume 9. New York: Plenum Press, 1986b.
- BENOWITZ, N.L. Increased 24-hour energy expenditure in cigarette smokers. (Letter.) *New England Journal of Medicine* 314(25):1640-1641, June 19, 1986c.
- BENOWITZ, N.L., HALL, S.M., HERNING, R.I., JACOB, P. III, JONES, R.T., OSMAN, A.-L. Smokers of low yield cigarettes do not consume less nicotine. *New England Journal of Medicine* 309(3):139-142, July 21, 1983.
- BENOWITZ, N.L., JACOB, P. III. Daily intake of nicotine during cigarette smoking. *Clinical Pharmacology and Therapeutics* 35(4):499-504, April 1984.
- BENOWITZ, N.L., JACOB, P. III. Nicotine renal excretion rate influences nicotine intake during cigarette smoking. *Journal of Pharmacology and Experimental Therapeutics* 234(1):153-155, July 1985.
- BENOWITZ, N.L., JACOB, P. III, JONES, R.T., ROSENBERG, J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. *Journal of Pharmacology and Experimental Therapeutics* 221(2):368-372, 1982.
- BENOWITZ, N.L., JACOB, P. III, KOZLOWSKI, L.T., YU, L. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. *New England Journal of Medicine* 315(21):1310-1313, November 20, 1986.
- BENOWITZ, N.L., JACOB, P. III, YU, L., TALCOTT, R., HALL, S., JONES, R.T. Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow- but not low-yield cigarettes. *Journal of the American Medical Association* 256(2):241-246, 1986.
- BENOWITZ, N.L., KUYT, F., JACOB, P. III. Circadian blood nicotine concentrations during cigarette smoking. *Clinical Pharmacology and Therapeutics* 32(6):758-764, December 1982.
- BENOWITZ, N.L., KUYT, F., JACOB, P. III. Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking. *Clinical Pharmacology and Therapeutics* 36(1):74-81, 1984.
- BENOWITZ, N.L., KUYT, F., JACOB, P. III, JONES, R.T., OSMAN, A.-L. Cotinine disposition and effects. *Clinical Pharmacology and Therapeutics* 309:139-142, 1983.
- BENOWITZ, N.L., LAKE, T., KELLER, K.H., LEE, B.L. Prolonged absorption with development of tolerance to toxic effects following cutaneous exposure to nicotine. *Clinical Pharmacology and Therapeutics* 42(1):119-120, 1987.
- BENOWITZ, N.L., PORCHET, H., SHEINER, L., JACOB, P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. *Clinical Pharmacology and Therapeutics*, in press.
- BENWELL, M.E.M., BALFOUR, D.J.K. Nicotine binding to brain tissue from drug-naive and nicotine-treated rats. *Journal of Pharmacy and Pharmacology* 37:405-409, 1985.
- BIBER, A., SCHERER, G., HOEPFNER, I., ADLKOFER, F., HELLER, W.-D., HADDOW, J.E., KNIGHT, G.J. Determination of nicotine and cotinine in human serum and urine: An interlaboratory study. *Toxicology Letters* 35:45-52, 1987.

- BJERCKE, R.J., COOK, G., RYCHLIK, N., GJIKA, H.B., VAN VUNAKIS, H., LANGONE, J.J. Stereospecific monoclonal antibodies to nicotine and cotinine and their use in enzyme-linked immunosorbent assays. *Journal of Immunological Methods* 90(2):203-213, June 24, 1986.
- BOOTH, J., BOYLAND, E. The metabolism of nicotine into two optically active stereoisomers of nicotine-oxide by animal tissues in vitro and by cigarette smokers. *Biochemistry and Pharmacology* 19(3):733-742, March 1970.
- BOVET, D., BOVET-NIITI, F. *Structure et Activite Pharmacodynamique des Medicaments du Systeme Nerveux Vegetatif Paris: S. Karger*, 1948, pp. 526-616.
- BOWMAN, E.R., MCKENNIS, N. Jr. Studies on the metabolism of (-)-cotinine in the human. *Journal of Pharmacology and Experimental Therapeutics* 135(3):306-311, 1962.
- BOYD, N.D., COHEN, J.B. Desensitization of membrane-bound *Torpedo* acetylcholine receptor by amine noncompetitive antagonists and aliphatic alcohols: Studies of (³H) acetylcholine binding and ²²Na⁺ ion fluxes. *Biochemistry* 23(18):4023-4033, August 1984.
- BRUNNEMANN, K.D., HOFFMANN, D. The pH of tobacco smoke. *Food and Cosmetics Toxicology* 12(1):115-124, February 1974.
- BUSH, L.P., GRUNWALD, C., DAVIS, D.L. Influence of puff frequency and puff volume on the alkaloid content of smoke. *Journal of Agricultural and Food Chemistry* 20(3):676-678, January-February 1972.
- CASTRO, A., MONJI, N., MALKUS, H., EISENHART, W., MCKENNIS, H. Jr., BOWMAN, E.R. Automated radioimmunoassay of nicotine. *Clinica Chimica Acta* 95(3):473-481, August 1979.
- CHANCE, W.T., KALLMAN, M.D., ROSECRANS, J.A., SPENCER, R.M. A comparison of nicotine and structurally related compounds as discriminative stimuli. *British Journal of Pharmacology* 63(4):609-616, August 1978.
- CHIEN, C.-Y., DIANA, J.N., CROOKS, P.A. High performance liquid chromatography with electrochemical detection for the determination of nicotine in plasma. *Journal of Pharmaceutical Sciences*, in press.
- CLARK, MSG., RAND, M.J. Effect of tobacco smoke on the knee-jerk reflex in man. *European Journal of Pharmacology* 3(4):294-302, July 1968.
- CLARK, M.S.G., RAND, M.J., VANOV, S. Comparison of pharmacological activity of nicotine and related alkaloids occurring in cigarette smoke. *Archives Internationales de Pharmacodynamie et de Therapie* 156(2):363-379, 1965.
- CLARKE, P.B.S., KUMAR, R. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. *British Journal of Pharmacology* 78(2):329-337, 1983a.
- CLARKE, P.B.S., KUMAR, R. Characterization of the locomotor stimulant action of nicotine in tolerant rats. *British Journal of Pharmacology* 80(3):587-594, November 1983b.
- CLARKE, P.B.S., KUMAR, R. Nicotine does not improve discrimination of brain stimulation reward by rats. *Psychopharmacology* 79(213):271-277, February 1983c.
- COMROE, J.H. The pharmacological actions of nicotine. *Annals of the New York Academy of Sciences* 90(1):48-51, September 27, 1960.
- COSTA, L.G., MURPHY, S.D. [³H]Nicotine binding in rat brain: Alteration after chronic acetylcholinesterase inhibition. *Journal of Pharmacology and Experimental Therapeutics* 226(2):392-397, August 1983.
- CUNDY, KC., GODIN, C.S., CROOKS, P.A. Stereospecific in vitro N-methylation of nicotine in guinea pig tissues by an S-adenosylmethionine-dependent N-methyltransferase. *Biochemical Pharmacology* 34:281-284, 1985.
- CURVALL, M., KAZEMI-VALA, E., ENZELL, C.R. Simultaneous determination of nicotine and cotinine in plasma using capillary column gas chromatography with nitrogen-sensitive detection. *Journal of Chromatography* 232:283-293, 1982.

- DAENENS, P., LARUELLE, L., CALLEWAERT, K., SCHEPPER, P., GALEAZZI, R., VAN ROSSUM, J. Determination of cotinine in biological fluids by capillary gas chromatography-mass spectrometry-selected-ion monitoring. *Journal of Chromatography* 342:79-87, 1985.
- DAJANI, R.M., GORROD, J.W., BECKETT, A.H. In vitro hepatic and extrahepatic reduction of (-)-nicotine-l'-N-oxide in rats. *Biochemical Pharmacology* 24:109-117, 1975a.
- DAJANI, R.M., GORROD, J.W., BECKETT, A.H. Reduction in vivo of (-)-nicotine-l'-N-oxide by germ-free and conventional rats. *Biochemical Pharmacology* 24:648-650, 1975b.
- DANAHER, B.G. Research on rapid smoking: Interim summary and recommendations. *Addictive Behaviors* 2:151-166, 1977.
- DAVIS, D.L., STEVENS, K.L., JURD, L. Chemistry of tobacco constituents. Oxidation of α -ionone and the acid catalyzed rearrangement of 5-keto- α -ionone. *Journal of Agricultural and Food Chemistry* 24(1):187-189, January-February 1976.
- DAVIS, R.A. The determination of nicotine and cotinine in plasma. *Journal of Chromatographic Science* 24(4):134-141, April 1986.
- DIXON, W.E., LEE, W.E. Tolerance to nicotine. *J. Exp. Physiol.* (London) 5:373-383, 1912.
- DUBE, M.F., GREEN, C.R. Methods of collection of smoke for analytical purposes. *Recent Advances in Tobacco Science* 8:42-102, October 1982.
- EGLE, J.L. Jr., HUDGINS, P.M. Dose-dependent sympathomimetic and cardioinhibitory effects of acrolein and formaldehyde in the anesthetized rat. *Toxicology and Applied Pharmacology* 28:358-366, 1974.
- ENZELL, C.R., WAHLBERG, I. Leaf composition in relation to smoking quality and aroma. *Recent Advances in Tobacco Science* 6:64-122, October 1980.
- EUDY, L.W., THOME, F.A., HEAVNER, D.L., GREEN, C.R., INGEBRETHSEN, B.J. *Studies on the Vapor Particulate-Phase Distribution of Environmental Nicotine by Selected Trapping and Detection Methods*. Paper presented at the 79th Tobacco Chemists' Research Conference, Montreal, October 2-5, 1985.
- FAULKNER, J.M. Nicotine poisoning by absorption through the skin. *Journal of the American Medical Association* 100(21):1664-1665, May 27, 1933.
- FEYERABEND, C., INGS, R.M., RUSSELL, M.A.H. Nicotine pharmacokinetics and its application to intake from smoking. *British Journal of Clinical Pharmacology* 19(2):239-247, February 1985.
- FEYERABEND, C., LEVITT, T., RUSSELL, M.A.H. A rapid gas-liquid chromatographic estimation of nicotine in biological fluids. *Journal of Pharmacy and Pharmacology* 27(6):434-436, June 1975.
- FRECKER, R.C. Eye movement measurement and the pharmacodynamics of tobacco dependence. In: *Proceedings of the 5th World Conference on Smoking and Health* 1:121-129, 1983.
- GARG, M. Variation in effects of nicotine in four strains of rats. *Psychopharmacologia* 14:432-438, 1969.
- GEHLBACH, S.H., WILLIAMS, W.A., PERRY, L.D., FREEMAN, J.I., LANGONE, J.J., PETA, L.V., VAN VUNAKIS, H. Nicotine absorption by workers harvesting green tobacco. *Lancet* 1(7905):478-480, March 1, 1975.
- GIORGUIEFF, M.F., Le FLOCH, M.L., GLOWINSKI, J., BESSON, M.J. Involvement of cholinergic presynaptic receptors of nicotinic and muscarinic types in the control of the spontaneous release of dopamine from striatal dopaminergic terminals in the rat. *Journal of Pharmacology and Experimental Therapeutics* 200(3):535-544, 1977.
- GIORGUIEFF-CHESELET, M.F., KEMEL, M.L., WANDSCHEER, D., GLOWINSKI, J. Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: Effect of nicotine in a low concentration. *Life Science* 25(14):1257-1262, 1979.

- GOLDFARB, T.L., GRITZ, E.R., JARVIK, M.E., STOLERMAN I.P. Reactions to cigarettes as a function of nicotine and "tar". *Clinical Pharmacology and Therapeutics* 19(6):767-772, June 1976.
- GORI, G.B., BENOWITZ, N.L., LYNCH, C.J. Mouth versus deep airways absorption of nicotine in cigarette smokers. *Pharmacology Biochemistry and Behavior* 25(6):1181-1184, December 1986.
- GREEN, M.A., EGGLE, J.L. Jr. The effects of acetaldehyde and acrolein on blood pressure in guanethidine-pretreated hypertensive rats. *Toxicology and Applied Pharmacology* 69(1):29-36, June 15, 1983.
- GRITZ, E.R. Smoking behavior and tobacco abuse. In: Mello, N.K. (ed.) *Advances in Substance Abuse*, Volume 1. Greenwich, Connecticut: JAI Press, 1980, pp. 91-158.
- GRITZ, E.R., BAER-WEISS, V., BENOWITZ, N.L., VAN VUNAKIS, H., JARVIK, M.E. Plasma nicotine and cotinine concentrations in habitual smokeless tobacco users. *Clinical Pharmacology and Therapeutics* 30(2):201-209, August 1981.
- GRUENKE, L.D., BEELEN, T.C., CRAIG, J.C., PETRAKIS, N.L. The determination of nicotine in biological fluids at picogram levels by selected ion recording. *Analytical Biochemistry* 94(2):411-416, April 15, 1979.
- GUILLERMAN, R., RADZISZEWSKI, E., CAILLE, J.E. Effects of carbon monoxide on performance in a vigilance task (automobile driving). In: Thornton, R.E. (ed.) *Smoking Behavior. Physiological and Psychological Influences*. London and New York: Churchill Livingstone, 1978.
- HALEY, N.J., AXELRAD, C.M., TILTON, K.A. Validation of self-reported smoking behavior: Biochemical analyses of cotinine and thiocyanate. *American Journal of Public Health* 73(10):1204-1207, October 1983.
- HALEY, N.J., HOFFMANN, D. Analysis for nicotine and cotinine in hair to determine cigarette smoker status. *Clinical Chemistry* 31(10):1598-1600, October 1985.
- HALL, G.H. Changes in body temperature produced by cholinomimetic substances injected into the cerebral ventricles of unanaesthetized cats. *British Journal of Pharmacology* 44(4):634-641, April 1972.
- HANCOCK, J.C., HENDERSON, E.G. Antinicotinic action of nicotine and lobeline on frog sartorius muscle. *Naunyn-Schmiedeberg's Archiv fur Pharmakologie* 272(3):307-324, 1972.
- HATCHELL, P.C., COLLINS, A.C. Influences of genotype and sex on behavioral tolerance to nicotine in mice. *Pharmacology Biochemistry and Behavior* 6(1):25-30, January 1977.
- HATCHELL, P.C., COLLINS, A.C. The influence of genotype and sex on behavioral sensitivity to nicotine in mice. *Psychopharmacology* 71(1):45-49, 1980.
- HECKMAN, R.A., DUBE, M.F., LYNN, D., RIVERS, J.M. The role of leaf precursors in cigarette flavor. In: *Tobacco Leaf Chemistry: Its Origin, Understanding and Current Trends. Recent Advances in Tobacco Science*, Volume 7. Proceedings of the 35th Tobacco Chemists Research Conference, Winston-Salem, North Carolina, 1981, pp. 107-153.
- HENDRY, J.S., ROSECRANS, J.A. The development of pharmacological tolerance to the effects of nicotine on schedule-controlled responding in mice. *Psychopharmacology* 77(4):339-343, 1982.
- HENGEN, N., HENGEN, M. Gas-liquid chromatographic determination of nicotine and cotinine in plasma. *Clinical Chemistry* 24(1):50-53, 1978.
- HENNINGFIELD, J.E. Behavioral pharmacology of cigarette smoking. In: Thompson, T., Dews, P.B. (eds.) *Advances in Behavioral Pharmacology*, Volume 4. New York: Academic Press, 1984, pp. 131-210.
- HENNINGFIELD, J.E., GOLDBERG, S.R. Nicotine as a reinforcer in human subjects and laboratory animals. *Pharmacology Biochemistry and Behavior* 19(6):989-992, 1983.

- HENNINGFIELD, J.E., MIYASATO, K., JASINSKI, D.R. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. *Journal of Pharmacology and Experimental Therapeutics* 234(1):1-12, July 1985.
- HERNING, R.I., JONES, R.T., BENOWITZ, N.L., MINES, A.H. How a cigarette is smoked determines nicotine blood levels. *Clinical Pharmacology and Therapeutics* 33(1):84-90, January 1983.
- HIBBERD, A.R., GORROD, J.W. Enzymology of the metabolic pathway from nicotine to cotinine, in vitro. *European Journal of Drug Metabolism and Pharmacokinetics* 8(2):151-162, 1983.
- HIBBERD, A.R., O'CONNOR, V., GORROD, J.W. Detection of nicotine, nicotine-1'-N-oxide and cotinine in maternal and foetal body fluids. In: Gorrod, J.W. (ed.) *Biological Oxidation of Nitrogen*. Amsterdam: Elsevier/North-Holland Biomedical Press, 1978, pp. 353-361.
- HILL, P., HALEY, N.J., WYNDER, E.L. Cigarette smoking: Carboxyhemoglobin, plasma nicotine, cotinine and thiocyanate vs self-reported smoking data and cardiovascular disease. *Journal of Chronic Diseases* 36(6):439-449, 1983.
- HILL, P., WYNDER, E.L. Nicotine and cotinine in breast fluid. *Cancer Letters* 6:251-254, 1979.
- HOBBIGER, F., MITCHELSON, F., RAND, M.J. The actions of some cholinomimetic drugs on the isolated taenia of the guinea-pig caecum. *British Journal of Pharmacology* 36:53-69, 1969.
- HOFFMANN, D., WYNDER, E.L. Smoke of cigarettes and little cigars. An analytical comparison. *Science* 178:1197-1199, 1977.
- HUBBARD, J.E., GOHD, R.S. Tolerance development to the arousal effects of nicotine. *Pharmacology Biochemistry and Behavior* 3(3):471-476, May-June 1975.
- INGENITO, A.J., BARRETT, J.P., PROCITA, L. Direct central and reflexly mediated effects of nicotine on the peripheral circulation. *European Journal of Pharmacology* 17(3):375-385, March 1972.
- INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. *Tobacco Smoking*, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Volume 38. World Health Organization, International Agency for Research on Cancer, 1986.
- ISAAC, P.F., RAND, M.J. Cigarette smoking and plasma levels of nicotine. *Nature* 236(5345):308-310, April 7, 1972.
- JACOB, P. III, BENOWITZ, N.L., SHULGIN, A.T. Recent studies of nicotine metabolism in humans. *Pharmacology Biochemistry and Behavior* 1988.
- JACOB, P. III, BENOWITZ, N.L., YU, L., SHULGIN, A.T. Determination of nicotine N-oxide by gas chromatography following thermal conversion to 2-methyl-6-(3-pyridyl)-tetrahydro-1,2 oxazine. *Analytical Chemistry* 58(11):2218-2221, September 1986.
- JACOB, P. III, WILSON, M., BENOWITZ, N.L. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. *Journal of Chromatography* 222(1):61-70, January 2, 1981.
- JAMES, T.N., BEAR, E.S., LANG, K.F., GREEN, E.W., WINKLER, H.H. Adrenergic mechanisms in the sinus node. *Archives of International Medicine* 125:513-547, March 1970.
- JARVIK, M. Biological factors underlying the smoking habit. In: Jarvik, M.E., Cullen, J.W., Griz, E.R., Vogt, T.M., West, L.J. (eds.) *Research on Smoking Behavior*, NIDA Research Monograph 17. U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse. DHEW Publication No. (ADM) 78-581, 1977, pp. 122-146.

- JARVIS, M., TUNSTALL-PEDOE, H., FEYERABEND, C., VESEY, C., SALLOOJEE, Y. Biochemical markers of smoke absorption and self reported exposure to passive smoking. *Journal of Epidemiology and Community Health* 38(4):335-339, December 1984.
- JENNER, P., GORROD, J.W., BECKETT, A.H. The absorption of nicotine-1'-N-oxide and its reduction in the gastro-intestinal tract in man. *Xenobiotica* 3(6):341-349, 1973.
- JONES, D., CURVALL, M., ABRAHAMSSON, L., KAZEMI-VALA, E., ENZELL, C.R. Quantitative analysis of plasma nicotine using selected ion monitoring at high resolution. *Biomedical Mass Spectrometry* 9(12):539-545, 1982.
- JONES, R.A. Individual differences in nicotine sensitivity. *Addictive Behaviors* 11(4):435-438, 1986.
- KACHUR, J.F., MAY, E.L., AWAYA, H., EGGLE, J.L., JR., ACETO, M.D., MARTIN, B.R. Pharmacological effects of 1,2,3,5,6,10b-hexahydropyrido[2,3-g]lizzdoline, a bridged-nicotine analog. *Life Sciences* 38(4):323-330, January 27, 1986.
- KANNE, D.B., ASHWORTH, D.J., CHENG, M.T., MUTTER, L.C., ABOOD, L.G. Synthesis of the first highly potent bridged nicotinoid. 9-Azabicyclo[4.2.1]nona[2,3-c]pyridine (Pyrido[3,4-b]homotropane). *Journal of the American Chemical Society* 108:7864-7865, 1986.
- KATZ, B., THESLEFF, S. A study of the "desensitization" produced by acetylcholine at the motor end-plate. *Journal of Physiology* (London) 138:63-80, 1957.
- KIRPEKAR, S.M., FURCHGOTT, R.F. Interaction of tryamine and guanethidine in the spleen of cat. *Journal of Pharmacology and Experimental Therapeutics* 180:38-46, 1972.
- KNIGHT, G.J., WYLIE, P., HOLMAN, M.S., HADDOW, J.E. Improved ¹²⁵I radioimmunoassay for cotinine by selective removal of bridge antibodies. *Clinical Chemistry* 31(1):118-121, January 1985.
- KSIR, C., HAKAN, R.L., KELLAR, K.J. Chronic nicotine and locomotor activity: Influences of exposure dose and test dose. *Psychopharmacology* 92:25-29, 1987.
- KSIR, C.J., HAKAN, R., HALL, D.P. Jr., KELLAR, K.J. Exposure to nicotine enhances behavioral stimulant effect of nicotine and increases binding of [³H]acetylcholine binding to nicotinic receptors. *Neuropharmacology* 24:527-532, 1985.
- KYEREMATEN, G.A., DAMIANO, M.D., DVORCHIK, B.H., VESELL, E.S. Smoking-induced changes in nicotine disposition: Application of a new HPLC assay for nicotine and its metabolites. *Clinical Pharmacology and Therapeutics* 32(6):769-780, December 1982.
- KYEREMATEN, G.A., DVORCHIK, B.H., VESELL, E.S. Influence of different forms of tobacco intake on nicotine elimination in man. *Pharmacology* 26(4):205-209, April 1983.
- LANGLEY, J.N. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. *Journal of Physiology* (London) 33:374-413, 1905.
- LANGONE, J.J., GJIKA, H.B., VAN VUNAKIS, H. Nicotine and its metabolites. Radioimmunoassays for nicotine and cotinine. *Biochemistry* 12(24):5025-5030, November 20, 1973.
- LANGONE, J.J., VAN VUNAKIS, H., HILL, P. Quantitation of cotinine in sera of smokers. *Research Communications in Chemical Pathology and Pharmacology* 10(1):21-28, January 1975.
- LARSON, P.S., HAAG, H.B. Studies on the fate of nicotine in the body III. On the pharmacology of some methylated and demethylated derivatives of nicotine. *Journal Pharmacology Experimental Therapeutics* 77:343-349, 1943.
- LEE, B.L., BENOWITZ, N.L., JACOB, P. III. Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. *Clinical Pharmacology and Therapeutics* 41(4):474-479, 1987.

- LUCK, W., HANSEN, R., STELDINGER, R., NAU, H. Nicotine and cotinine--Two pharmacologically active substances as parameters for the strain on fetuses and babies of mothers who smoke. *Journal of Perinatal Medicine* 10(52):107-108, 1982.
- MACHACEK, D.A., JIANG, N. Quantification of cotinine in plasma and saliva by liquid chromatography. *Clinical Chemistry* 32(6):979-982, June 13, 1986.
- MARKS, M.J., BURCH, J.B., COLLINS, A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. *Journal of Pharmacology and Experimental Therapeutics* 226(3):817-825, 1983a.
- MARKS, M.J., BURCH, J.B., COLLINS, A.C. Genetics of nicotine response in four inbred strains of mice. *Journal of Pharmacology and Experimental Therapeutics* 226(1):291-302, 1983b.
- MARKS, M.J., COLLINS, A.C. Characterization of nicotine binding in mouse brain and comparison with the binding of *a*-bungarotoxin and quinuclidinyl benzilate. *Molecular Pharmacology* 22(3):554-564, November 1982.
- MARKS, M.J., COLLINS, A.C. Tolerance, cross-tolerance, and receptors after chronic nicotine or oxotremorine. *Pharmacology Biochemistry and Behavior* 22(2):283-291, 1985.
- MARKS, M.J., ROMM, E., BEALER, S., COLLINS, A.C. A test battery for measuring nicotine effects in mice. *Pharmacology Biochemistry and Behavior* 23(2):325-330, August 1985.
- MARKS, M.J., ROMM, E., GAFFNEY, D.K., COLLINS, A.C. Nicotine-induced tolerance and receptor changes in four mouse strains. *Journal of Pharmacology and Experimental Therapeutics* 237(3):809-819, 1986.
- MARKS, M.J., STITZEL, J.A., COLLINS, A.C. Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. *Journal of Pharmacology and Experimental Therapeutics* 235(3):619-628, December 1985.
- MARKS, M.J., STITZEL, J.A., COLLINS, A.C. Dose-response analysis of nicotine tolerance and receptor changes in two inbred mouse strains. *Journal of Pharmacology and Experimental Therapeutics* 239(2):358-364, November 1986.
- MARKS, M.J., STITZEL, J.A., COLLINS, A.C. Influence of kinetics on nicotine administration on tolerance development and receptor levels. *Pharmacology Biochemistry and Behavior* 27:505-512, 1987.
- MARKS, M.J., STITZEL, J.A., ROMM, E., WEHNER, J.M., COLLINS, A.C. Nicotinic binding sites in rat and mouse brain: Comparison of acetylcholine, nicotine and *a*-bungarotoxin. *Molecular Pharmacology* 30(5):427-436, November 1986.
- MARTIN, W.R., SLOAN, J.W., HOOK, R., KAPLAN, E., WASH, C. Fourth ventricle effects of nicotine, 2-methylpiperidine and cytosine in dogs. *Pharmacology Biochemistry and Behavior* 25(4):843-848, October 1986.
- MARTINO-BARROWS, A.M., KELLAR, K.J. [³H]Acetylcholine and [³H](-)nicotine label the same recognition site in rat brain. *Molecular Pharmacology* 31:169-174, February 1987.
- MAZIERE, M., COMAR, D., MARZANO, C., BERGER, G. Nicotine-¹¹C: Synthesis and distribution kinetics in animals. *European Journal of Nuclear Medicine* 1:255-258, 1976.
- MCCARTHY, L.E., BORISON, H.L. Separation of central effects of CO₂ and nicotine on ventilation and blood pressure. *Respiratory Physiology* 15(3):321-330, July 1972.
- MCCUSKER, K., McNABB, E., BONE, R. Plasma nicotine levels in pipe smokers. *Journal of the American Medical Association* 248(5):577-578, August 1982.
- McKENNIS, H. Jr., SCHWARTZ, S.L., BOWMAN, E.R. Alternate routes in the metabolic degradation of the pyrrolidine ring of nicotine. *Journal of Biological Chemistry* 239(11):3990-3996, November 1964.
- McKENNIS, H. Jr., TURNBULL, L.B., BOWMAN, E.R. N-Methylation of nicotine and cotinine in vivo. *Journal of Biological Chemistry* 238:719-723, 1963.

- McKENNIS, H. Jr., TURNBULL, L.B., BOWMAN, E.R., TAMAKI, E. The synthesis of hydroxycotinine and studies on its structure. *Journal of Organic Chemistry* 28(1):383-387, February 1963.
- MINER, L.L., MARKS, M.J., COLLINS, A.C. Classical genetic analysis of nicotine-induced seizures and nicotinic receptors. *Journal of Pharmacology and Experimental Therapeutics* 231(3):545-554, December 1984.
- MINER, L.L., MARKS, M.J., COLLINS, A.C. Genetic analysis of nicotine-induced seizures and hippocampal nicotinic receptors in the mouse. *Journal of Pharmacology and Experimental Therapeutics* 239(3):853-860, 1986.
- MORRISON, C.F., STEPHENSON, J.A. The occurrence of tolerance to a central depressant effect of nicotine. *British Journal of Pharmacology* 46(1):151-156, September 1972.
- MORROW, A.L., LOY, R., CREESE, I. Alteration of nicotinic cholinergic agonist binding sites in hippocampus after fimbria transection. *Brain Research* 334(2):309-314, May 20, 1985.
- NESBITT, P.D. Smoking, physiological arousal, and emotional response. *Journal of Personality and Social Psychology* 25(1):137-144, January 1973.
- NEURATH, G.B., DUNGER, M., ORTH, D., PEIN, F.G. Trans-3'-hydroxycotinine as a main metabolite in urine of smokers. *International Archives of Occupational and Environmental Health* 59(2):199-201, February 1987.
- OLDENDORF, W.H. Lipid solubility and drug penetration in the blood-brain barrier. *Proceedings of the Society for Experimental Biology and Medicine* 147:813-816, 1974.
- PETERSEN, D.R., NORRIS, K.J., THOMPSON, J.A. A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. *Drug Metabolism and Disposition* 12(6):725-731, November-December 1984.
- PETERSON, L.A., TREVOR, A., CASTAGNOLI, N. Jr. Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine D¹⁽⁵⁾-iminium species. *Journal of Medicinal Chemistry* 30(2):249-254, February 1987.
- PETRAKIS, N.L., GRUENKE, L.D., BEELEN, T.C., CASTAGNOLI, N., CRAIG, J.C. Nicotine in breast fluid of nonlactating women. *Science* 199(4326):303-305, January 20, 1978.
- PIADE, J.J., HOFFMANN, D. Chemical studies on tobacco smoke LXVII. Quantitative determination of alkaloids in tobacco by liquid chromatography. *Journal of Liquid Chromatography* 3(10):1505-1515, 1980.
- PILLSBURY, H.C., BRIGHT, C.C., O'CONNOR, K.J., IRISH, F.W. Tar and nicotine in cigarette smoke. *Journal of the Association of Official Analytical Chemists* 52(3):458-462, May 1969.
- POOL, W.F. *R-(+)-N-Methylnicotinium Ion and Nicotine Metabolism*. Doctoral Dissertation. University of Kentucky, Lexington, Kentucky, 1987.
- POOL, W.F., GODIN, C.S., CROOKS, P.A. Nicotine racemization during cigarette smoking. (Abstract.) *Toxicologist* 5:232, 1985.
- PORSIUS, A.J., VAN ZWIETEN, P.A. The central actions of nicotine on blood pressure and heart rate after administration via the left vertebral artery of anesthetized cats. Distribution of nicotine into the brain after central application. *Arzneimittel-Forschung/Drug Research* 28(9):1628-1631, 1978.
- RATHKAMP, G., TSO, T.C., HOFFMANN, D. Chemical studies on tobacco smoke. XX: Smoke analysis of cigarettes made from bright tobaccos differing in variety and stalk positions. *Beitrage zur Tobakforschung* 7(3):179-189, November 1973.
- ROPPOLO, J.R., KAWAMURA, H., DOMINO, E.F. Effects of cholinergic agonists and antagonists on lateral geniculate nucleus neurons. (Abstract.) *Pharmacologist* 12(2):270, Fall 1970.
- ROSE, J.E., TASHKIN, D.P., ERTLE, A., ZINSER, M.C., LAFER, R. Sensory blockade of smoking satisfaction. *Pharmacology Biochemistry and Behavior* 23(2):289-293, August 1985.

- ROSECRANS, J.A. Brain area nicotine levels in male and female rats with different levels of spontaneous activity. *Neuropharmacology* 11(6):863-870, November 1972.
- ROSECRANS, J.A., SCHECHTER, M.D. Brain area nicotine levels in male and female rats of two strains. *Archives Internationales de Pharmacodynamie et de Therapie* 196:46-54, 1972.
- ROSENBERG, J., BENOWITZ, N.L., JACOB, P., WILSON, K.M. Disposition kinetics and effects of intravenous nicotine. *Clinical Pharmacology and Therapeutics* 28(4):517-522, October 1980.
- RUSSELL, M.A.H. Tobacco smoking and nicotine dependence. In: Gibbins, R.J., Israel, Y., Kalant, H., Popham, R.E., Schmidt, W., Smart, R.G. (eds.) *Research Advances in Alcohol and Drug Problems*. New York: John Wiley and Sons, 1976, pp. 1-47.
- RUSSELL, M.A.H., FEYERABEND, C. Cigarette smoking: A dependence on high-nicotine boli. *Drug Metabolism Reviews* 8(1):29-57, 1978.
- RUSSELL, M.A.H., JARVIS, M.J., DEVITT, G., FEYERABEND, C. Nicotine intake by snuff users. *British Medical Journal* 283(6295):814-817, September 26, 1981.
- RUSSELL, M.A.H., RAW, M., JARVIS, M.J. Clinical use of nicotine chewing gum. *British Medical Journal* 280(6231):1599-1602, June 28, 1980.
- SAKMANN, B., PATLAK, J., NEHER, E. Single acetylcholine-activated channels show burst-kinetics in presence of desensitizing concentrations of agonist. *Nature* 286(3):71-73, July 1980.
- SASSON, I.M., HALEY, N.J., HOFFMANN, D., WYNDER, E.L., HELLBERG, D., NILSSON, S. Cigarette smoking and neoplasia of the uterine cervix: Smoke constituents in cervical mucus. (Letter.) *New England Journal of Medicine* 312(5):315-316, January 31, 1985.
- SAXENA, K., SCHEMAN, A. Suicide plan by nicotine poisoning: A review of nicotine toxicity. *Veterinary and Human Toxicology* 27(6):495-497, December 1985.
- SCHACHTER, S. Pharmacological and psychological determinants of smoking. In: Thornton, R.E. (ed.) *Smoking Behavior: Physiological and Psychological Influences*. London and New York: Churchill Livingstone, 1978.
- SCHIEVELBEIN, H. Nicotine, resorption and fate. *Pharmacology and Therapeutics* 18(2):233-247, 1982.
- SCHIEVELBEIN, H., EBERHARDT, R., LOESCHENKOHL, K., RAHLFS, V., BEDALL, F.K. Absorption of nicotine through the oral mucosa. I. Measurement of nicotine concentration in the blood after application of nicotine and total particulate matter. *Agents and Actions* 3(4):254-258, November 1973.
- SCHIEVELBEIN, H., HEINEMANN, G., LOESCHENKOHL, K., TROLL, C., SCHLEGEL, J. Metabolic aspects of smoking behavior. In: Thornton, R.E. (ed.) *Smoking Behavior: Physiological and Psychological Influences*. Edinburgh: Churchill Livingstone, 1978.
- SCHLATTER, J., BATTIG, K. Differential effects of nicotine and amphetamine on locomotor activity and maze exploration in two rat lines. *Psychopharmacology* 64(2):155-161, 1979.
- SCHMELTZ, I., HOFFMANN, D. Nitrogen-containing compounds in tobacco and tobacco smoke. *Chemical Reviews* 77(3):295-311, June 1977.
- SCHMITERLOW, C.G., HANSSON, E., ANDERSSON, G., APPLGREN, L.-E., HOFFMANN, P.C. Distribution of nicotine in the central nervous system. *Annals of the New York Academy of Science* 142:2-14, 1967.
- SCHWARTZ, R.D., KELLAR, K.J. In vivo regulation of [³H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. *Journal of Neurochemistry* 45(2):427-433, August 1985.
- SCHWARTZ, R.D., MCGEE, R., KELLAR, K.J. Nicotinic cholinergic receptors labeled by [³H]acetylcholine in rat brain. *Molecular Pharmacology* 22(1):56-62, July 1982.

- SEPKOVIC, D.W., HALEY, N.J., AXELRAD, C.M., LAVOIE, E.J. Thyroid hormone concentrations in rats after chronic nicotine metabolite administration. *Proceedings of the Society for Experimental Biology and Medicine* 177(3):412-416, December 1984.
- SEPKOVIC, D.W., HALEY, N.J., AXELRAD, C.M., SHIGEMATSU, A., LAVOIE, E.J. Short-term studies on the in vivo metabolism of N-oxides of nicotine in rats. *Journal of Toxicology and Environmental Health* 18(2):205-214, 1986.
- SHARP, B.M., BEYER, H.S. Rapid desensitization of the acute stimulatory effects of nicotine on plasma adrenocorticotropin and prolactin. *Journal of Pharmacology and Experimental Therapeutics* 238(2):486-491, 1986.
- SHIBATA, S., HATTORI, K., SANDERS, B. The relationship between external calcium concentration and the recovery rate of aortic strips from nicotine tachyphylaxis. *European Journal of Pharmacology* 16(1):109-112, September 1971.
- SHIMAMOTO, K., OYAZU, S., KAWAI, K., KANAMITSU, O. On the pharmacological action of nicotine methiodides. *Folia Pharmacologica Japonica* 54:55-5, 1958.
- SHULGIN, A.T., JACOB, P. III, BENOWITZ, N.L., LAU, D. Identification and quantitative analysis of cotinine-N-oxide in human urine. *Journal of Chromatography*, 1987, in press.
- SLOAN, J.W., MARTIN, W.R., BOSTWICK, M., HOOK, R., WALA, E. The comparative binding characteristics of nicotinic ligands and their pharmacology. *Pharmacology Biochemistry and Behavior* 26, 1987
- SLOAN, J.W., MARTIN, W.R., HOOK, R., HERNANDEZ, J. Structure-activity relationships of some pyridine, piperidine and pyrrolidine analogues for enhancing and inhibiting the binding of (plus or minus)-[³H]nicotine to rat brain P₂ preparation. *Journal of Medicinal Chemistry* 28(9):1245-1251, September 1985.
- SNOOK, M.E., CHORTYK, O.T. The rigid determination of harman and norharman in cigarette smoke. *Tobacco Science* 28:36-40, 1984.
- STALHANDSKE, T. Effects of increased liver metabolism of nicotine on its uptake, elimination and toxicity in mice. *Acta Physiologica Scandinavica* 80(2):222-234, October 1970.
- STALHANDSKE, T., SLANINA, P. Nicotyrine inhibits in vivo metabolism of nicotine without increasing its toxicity. *Toxicology and Applied Pharmacology* 65(3):366-372, September 30, 1982.
- STEWART, R.D., BARETTA, E.D., PLATTE, L.R., STEWART, E.B., KALBFLEISCH, J.H., VAN YSERLOO, B., RIMM, A.A. Carboxyhemoglobin levels in American blood donors. *Journal of the American Medical Association* 229(9):1187-1195, August 26, 1974.
- STITZER, M., MORRISON, J., DOMINO, E.F. Effects of nicotine on fixed-interval behavior and their modification by cholinergic antagonists. *Journal of Pharmacology and Experimental Therapeutics* 171(2):166-177, February 1970.
- STOLERMAN, I.P., BUNKER, P., JARVIK, M.E. Nicotine tolerance in rats; Role of dose and dose interval. *Psychopharmacologia* 34:317-324, 1974.
- STOLERMAN, I.P., FINK, R., JARVIK, M.E. Acute and chronic tolerance to nicotine measured by activity in rats. *Psychopharmacologia* 30(4):329-342, 1973.
- SU, C. Actions of nicotine and smoking on circulation. *Pharmacology and Therapeutics* 17(1):129-141, 1982.
- SUTTON, S.R., RUSSELL, M.A.H., IYER, I., FEYERABEND, C., SALOOJEE, Y. Relationship between cigarette yields, puffing patterns, and smoke intake: Evidence for tar compensation? *British Medical Journal* 285(6342):600-603, August 28-September 4, 1982.
- TAKEUCHI, M., KUROGOCHI, Y., YAMAOKA, M. Experiments on the repeated injection of nicotine into albino rats. *Folia Pharmacologica Japonica* 50:66-69, 1954.

- TEPPER, J.M., WILSON, J.R., SCHLESINGER, K. Relations between nicotine-induced convulsive behavior and blood and brain levels of nicotine as a function of sex and age in two inbred strains of mice. *Pharmacology Biochemistry and Behavior* 10:349-353, 1979.
- THORNTON, R.E. *Smoking Behavior, Physiological and Psychological Influences*. London and New York: Churchill Livingstone, 1978.
- TORREILLES, J., GUERIN, M.-C., PREVIERO, A. Des structures simples aux potentialites pharmacologiques elevees: Les β -carbolines. Origines, syntheses, proprietes biologiques. *Biochimie* 67:929-947, 1985.
- TRAVELL, J. Absorption of nicotine from various sites. *Annals of the New York Academy of Sciences* 90(1):13-30, September 27, 1960.
- TURNER, D.M., ARMITAGE, A.K., BRIANT, R.H., DOLLERY, C.T. Metabolism of nicotine by the isolated perfused dog lung. *Xenobiotica* 5(9):539-551, 1975.
- TURNER, J.A.M., SILLETT, R.W., McNICOL, M.W. Effect of cigar smoking on carboxyhaemoglobin and plasma nicotine concentrations in primary pipe and cigar smokers and ex-cigarette smokers. *British Medical Journal* 2(6099):1387-1389, November 26, 1977.
- U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. *The Health Consequences of Smoking: Cardiovascular Disease. A Report of the Surgeon General*. U.S. Department of Health and Human Services, Public Health Service, Office on Smoking and Health. DHHS Publication No. (PHS) 84-50204, 1983.
- VAN LOON, G.R., KIRITSY-ROY, J.A., BROWN, L.V., BOBBITT, F.A. Nicotinic regulation of sympathoadrenal catecholamine secretion. In: Martin, W.R., Van Loon, G.R., Iwamoto, E.T., Davis, L. (eds.) *Tobacco Smoking and Nicotine*. New York: Plenum Press, 1987, pp. 263-276.
- VAN VUNAKIS, H., LANGONE, J.J., MILUNSKY, A. Nicotine and cotinine in the amniotic fluid of smokers in the second trimester of pregnancy. *American Journal of Obstetrics and Gynecology* 120(1):64-66, September 1974.
- VEREBEY, K.G., DEPACE, A., MULE, S.J. A rapid, quantitative GLC method for the simultaneous determination of nicotine and cotinine. *Journal of Analytical Toxicology* 6:294-296, November-December 1982.
- WALD, N.J., BOREHAM, J., BAILEY, A., RITCHIE, C., HADDOW, J.E., KNIGHT, G. Urinary cotinine as marker of breathing other people's tobacco smoke. (Letter.) *Lancet* 1(8370):230-231, January 28, 1984.
- WALD, N., HOWARD, S., SMITH, P.G., BAILEY, A. Use of carboxyhaemoglobin levels to predict the development of diseases associated with cigarette smoking. *Thorax* 30:133-140, 1975.
- WALD, N.J., IDLE, M., BOREHAM, J., BAILEY, A. Inhaling habits among smokers of different types of cigarette. *Thorax* 35(12):925-928, December 1980.
- WALD, N.J., IDLE, M., BOREHAM, J., BAILEY, A. Carbon monoxide in breath in relation to smoking and carboxyhemoglobin levels. *Thorax* 36(5):366-366, May 1981.
- WEILAND, G., GEORGIA, B., LAPPA, S., CHIGNELL, CF., TAYLOR, P. Kinetics of agonist-mediated transitions in state of the cholinergic receptor. *Journal of Biological Chemistry* 252(21):7648-7656, November 10, 1977.
- WENZEL, D.G., AZMEH, N., CLARK, I.J. Studies on the acute and chronic depressor actions of nicotine in the rat. *Archives Internationales de Pharmacodynamie et de Therapie* 193(1):23-36, September 1971.
- WEST, R.J., RUSSELL, M.A.H. Cardiovascular and subjective effects of smoking before and after 24 h of abstinence from cigarettes. *Psychopharmacology* 92:118-121, 1987.
- WESTFALL, T.C. Effect of nicotine and other drugs on the release of ^3H -norepinephrine and ^3H -dopamine from rat brain slices. *Neuropharmacology* 13(8):693-700, August 1974.

- WESTFALL, T.C., PERRY, H. The nicotinic-induced release of endogenous dopamine from rat striatal slices from animals chronically exposed to dimethylphenylpiperazine (DMPP). *Neuroscience Letters* 71(3):340-344, November 21, 1986.
- WOOD, J.D. Electrophysiological and pharmacological properties of the stomach of the squid *loligo pealii* (Lesueur). *Comparative Biochemistry and Physiology* 30(5):813-824, September 1, 1969.
- WRIGHT, G., RANDELL, P., SHEPHARD, R.J. Carbon monoxide and driving skills. *Archives of Environmental Health* 27(6):349-354, December 1973.
- ZEIDENBERG, P., JAFFE, J.H., KANZLER, M., LEVITT, M.D., LANGONE, J.J., VAN VUNAKIS, H. Nicotine: Cotinine levels in blood during cessation of smoking. *Comprehensive Psychiatry* 18(1):93-101, January-February 1977.